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Expression QTL (eQTL) detection has emerged as an important tool for unravelling 
the relationship between genetic risk factors and disease or clinical phenotypes. Most 
studies focus on analyses predicated on the assumption that only a single causal variant 
explains the association signal in each interval.  This greatly simplifies the statistical 
modeling, but is liable to biases in scenarios where multiple linked causal-variants are 
responsible. Here in this thesis, my primary goal was to address the prevalence of 
secondary cis-eQTL signals regulating peripheral blood gene expression locally, utilizing 
two large human cohort studies, each greater than 2,500 samples with accompanying whole 
genome genotypes.  The CAGE dataset is a compendium of Illumina microarray studies, 
and the Framingham Heart Study (FHS) is a two-generation Affymetrix dataset. I firstly 
describe performing simulation to reveal the potential interference of causal variants in LD 
regions. I then also describe a Bayesian co-localization analysis of the extent of sharing of 
cis-eQTL detected in both studies as well as with the BIOS RNA-seq dataset. Stepwise 
conditional modeling demonstrates that multiple eQTL signals are present for ~40% of 
over 3,500 eGenes in both microarray datasets, and that the number of loci with additional 
signals reduces by approximately two-thirds with each conditioning step. Although fewer 
than 20% of the peak signals across platforms fine-map to the same credible interval, the 
co-localization analysis finds that as many as 50%~60% of the primary eQTL are actually 
shared. Subsequently, co-localization of eQTL signals with GWAS hits detected 1,349 
genes whose expression in peripheral blood is associated with 591 human phenotype traits 
or diseases, including enrichment for genes with regulatory functions such as protein kinase 
xiii 
 
activity and DNA binding.  Just one quarter of these co-localization signals are replicated, 
further highlighting the technological and methodological barriers to reconciliation of 
GWAS and eQTL signals. My results are provided as a web-based resource for 
visualization of multi-site regulation of gene expression and their association with human 
complex traits and disease states. In addition to the cis-eQTL study, as a member of the 
eQTLgen consortium, I also conduct trans-eQTL detection in multiple cohorts, including 
FHS, which contains related individuals, and performed cis-trans eQTL mediation 
analysis, which I will report as a side project.  This thesis provides novel insights into the 
complexity of gene regulation and the low consistency of fine mapping across studies, and 





CHAPTER 1.  
INTRODUCTION 
1.1 Background of eQTL analysis 
Despite low levels of nucleotide diversity in humans, and less than 0.5% amino acid 
sequence divergence for orthologous proteins between human and chimpanzee 
(International Human Genome Sequencing Consortium, 2005), there are  obvious profound 
differences across a broad spectrum of phenotypes between these two species.  These and 
other observations highlight the importance of gene regulation (Jacob and Monod 1961), 
instead of protein function, for phenotypic evolution. Moreover, heritability analysis with 
twin-studies in the past half century has demonstrated that for many human traits, half or 
more of the phenotype variance can be explained by genetic factors (Polderman et al. 2015) 
(Gusev et al. 2014). Over 90% of GWAS hits locate in non-coding regions, indicating that 
these regions likely manifest their effects through regulation of gene expression (Manolio 
et al. 2009), consistent with further evidence that variants in the vicinity of DNaseI 
hypersensitive sites (DHS) capture most of the heritability. In parallel, evolutionary studies 
of cis-regulatory regions have illustrated that regulatory elements seem to contribute 
substantially to both adaptive substitutions and deleterious polymorphisms. Thus, 
understanding the mechanisms that regulate human gene expression is not only crucial for 
basic biology but also for the interpretation of which polymorphisms at human disease loci 
are causal (Torgerson et al. 2009).  
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Currently, the most direct genome-wide approach to dissect the effect of genetic 
variation on gene expression is expression Quantitative Trait Locus (eQTL) analysis 
(GTEx Consortium 2015), as illustrated in Figure 1.1.  Expression of gene B is regulated 
by two regulatory elements, one of which (green rectangle) is a transcription factor binding 
site, which is bound by a transcription factor in a sequence-specific manner. In a population 
of individuals, if a site in the TFBS (red star) has two alleles, C and T, then individuals 
with T, on average, may for example have a higher expression than C. Once the genotype 
and expression levels for samples from the population have been obtained, we can perform 
association or linkage analysis to verify the relationship between phenotype and biomarker. 
With the advance of next generation sequencing technology, personalized medicine 
or precision medicine is becoming increasingly prevalent in human health studies. These 
approaches assume that patients are unique, having their own characteristics and distinct 
responses to disease or drugs.  The goal is to assign patients into different groups according 
to genetic or genomic biomarker information, which is then used to guide doctors’ medical 
recommendations. I hypothesize that the application of eQTL studies will not only greatly 
broaden our understanding of personal transcriptomes, but can also be used to improve the 
Figure 1.1 Diagram of eQTL and eQTL detection. 
 3 
accuracy of personalized medicine. Although current application of personalized medicine 
is still immature, some studies have already demonstrated the usefulness in personalized 
medicine by integrating eQTL with GWAS to predict phenotype trait and disease. TWAS 
predicts gene expression with detected eQTL sites, and regression of these predictions onto 
phenotype traits may provide greater accuracy than previous genetic risk score methods. 
Also, in the Gibson lab, an approach named Transcriptional Risk Score (TRS) analysis has 
been developed in which causal genes for the phenotype trait are first evaluated for joint 
GWAS and eQTL associations, and then expression levels for the significant genes are 
summed in order to measure the risk of disease. It has been shown to provide greater 
prediction power than previous methods for autoimmune diseases such as Crohn’s disease 
(Marigorta et al, 2017). 
1.2 Definition of eQTL 
eQTL are genomic regions which contain variants contributing to variance in gene 
expression. Heritability studies partition the sources of phenotype variance in a population 
into contributions from two broad categories, environmental and genetic factors.  
Environmental factors, like food resource, life style, development stage, influence all 
individuals, while micro-environmental stochastic effects are also recognized.  Genetic 
variation is due to all of the DNA sequence polymorphisms occurring on one individual 
genome. There are multiple kinds of genetic variants, including single nucleotide 
polymorphism (SNP), copy number variation (CNV), and structural variation (SV).  
Recently, the importance of epigenetic modifications, namely heritable factors that do not 
change the DNA sequence but do alter chromatin function, have been recognized as a third 
important  source of variability.  Interactions between these categories also contribute, but 
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are more difficult to detect.  eQTL are polymorphisms or mutations that affect regions on 
the chromosome that are crucial for control of transcript abundance, and hence are 
identified as regulatory variants. They alter regulatory elements such as promoters and 
enhancers, influencing the rate of transcription, or affect splice sites leading to alternative 
splicing, and some mutations change the folding characteristics of transcripts and hence 
mRNA stability.  
1.2.1 Classification of eQTL 
Based on biological characteristics, eQTLs can be further classified. According to 
the distance to the target gene, they may be trans-eQTL or cis-eQTL.  Trans-eQTL are 
located at a different locus, operationally defined as being on a different chromosome than 
the target gene, or on the same chromosome but a long distance (>1 Mb) from the target 
gene. cis-eQTL lie in the neighborhood of the target gene, where they are thought to affect 
gene expression by directly modulating RNA transcription and processing.  Technically, 
cis-eQTL are on the same chromosome of a diploid pair, so the definition based on location 
within 1 Mb of the Transcription Start Site (TSS) more correctly defines local-eQTL, but 
the term cis-eQTL is more commonly used in the literature. 
A limitation of eQTL detection is the study design. Although the expense of next 
generation sequencing has greatly reduced, most studies only consist of several hundred 
individuals.  By collecting samples from different cohorts, statistical power can largely be 
increased, and reduce the incidence of false positives. However, it is almost unavoidable 
that samples are included from different populations, including perhaps some from 
European and some from Asian populations. The existence of population structure results 
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in false positives and in some cases may suppress signals. Control for population structure 
has become a standard statistical procedure utilizing principal component analysis. Mixed-
linear modeling is widely used, and has been shown to be statistically optimal (Loh et al., 
2018). 
Considering statistical properties of the influence of SNPs on gene expression, there 
are several ways to classify eQTLs.  Most common are additive eQTL, which function in 
an additive manner where each of the two allele increases or decreases transcript abundance 
by the same amount. For example, suppose that an eQTL A, which for simplicity I assume 
to be a bi-allelic variant with alleles M and m, where the M allele increases the gene 
expression, affects a neighboring gene B. The average increase due to each M allele carried 
by an individual is fixed, and is called the allelic effect size, or substitution effect.  
Homozygotes MM have twice as much expression as heterozgygotes relative to mm, 
irrespective of other alleles.  Dominant or recessive eQTL effects are thought to be rare, 
since each chromosome contributes independently to the total gene expression.  Recently, 
another form of eQTL has also been explored: variance or v-eQTL, in which, instead of 
increasing mean expression, the allele changes the variance of expression among 
genotypes.  For example, the expression variance of individuals with MM is different from 
that of individuals with Mm and/or mm genotypes (Metzger et al. 2015; Gusev et al. 2016; 
Yang et al. 2016). There may be different sources of v-eQTL effects, one of which is 
epistasis, where the effect of a specific allele is conditional on the allele type at other sites, 
and this is now thought to be a potential source of unexplained human phenotypic variation. 
Another one is that variants may work independently to affect the variability of gene 
expression, perhaps by disrupting the stability of the transcription process. Metzger et al 
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(2015) investigated how mutation contributes to variance of gene expression in yeast by 
experimentally determining the effects of polymorphisms segregating in a gene promoter.  
They found that selection on expression noise resulting from v-eQTL has as large an impact 
on allele frequency variation as selection on mean expression level. 
1.2.2 Detection of eQTL 
Current application of cis-eQTL for GWAS interpretation generally requires that 
the individuals who are genotyped and phenotyped are from the same selected population. 
Based on the genotyping data (e.g. obtained with SNP arrays) one has to select informative 
markers, i.e. markers that are polymorphic in the study population. Expression data from 
DNA microarrays should undergo pre-processing (including background estimation and 
correction, probe set summary, and normalization) to be suitable for use in the subsequent 
steps. If other platforms for the expression measurements are used, appropriate pre-
processing and data summarization procedures should also be performed prior to eQTL 
mapping. For the defined cis-region of a specific gene, all variants are associated against 
the gene’s expression in a univariate fashion, and the statistical signals are then compared 
with GWAS. In cis-eQTL detection, the number of explored variants is hundreds to 
thousands, and the burden of multiple test correction is relatively small, so the statistical 
power is still high even with the most conservative correction method, Bonferroni 
correction. However, trans-eQTL detection requires testing of millions variants, so 
multiple test correction may obscure all signals, especially if the data set is limited to a few 
hundred individuals because of the expense and logistical difficulty of acquisition. So, most 
studies to date have concentrated on mapping cis-acting eQTLs (local to the gene region).  
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1.3 History of eQTL analysis in humans  
The idea of eQTL detection, merging expression with genomic variation, dates back 
to 2001 (Jansen and Nap, 2001) who called the strategy “genetical genomics”. Just one 
year later, in 2002, the first eQTL study in yeast was published in Science (Brem et al. 
2002), and in the same year, the first eQTL on human lymphoblastoid cell lines (LCL) was 
also published (Yan et al. 2002). A year later, Schadt et al. and Cheung et al. explored the 
genetic regulation of gene expression using variance component decomposition, 
demonstrating significant expression similarity among family members and inferring the 
existence of widespread contributions of genetic variation (Cheung et al. 2003; Schadt et 
al. 2003). The breakthrough paper in the human eQTL field was published in 2005 by 
Cheung et al., in which genome-wide high density SNP variants were linked to gene 
expression levels measured with microarray technology (Cheung et al. 2005).  The first 
true genome-wide eQTL association study was reported by Stranger et al in 2007, and 
included comparison of multiple populations. 
Since then, eQTL analyses have become prevalent in human genetics and by 2017, 
more than 100 eQTL studies have been published on human tissues. As shown in Table 1, 
the main tissues have been whole blood or LCL. In the early stage of eQTL analysis, the 
studied subjects were gathered from public data repositories such as CEPH, HapMap, or 
1000 Genomes, and usually limited samples were available for analysis (usually <300 
individuals). Eager to obtain more detailed information about gene expression and human 
complex traits, researchers have recently conducted more and more eQTL studies in non-
blood tissues, including liver and brain, or under different environmental circumstances 
and across diverse populations. Since 2015, RNA-seq and whole-genome sequencing 
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technology have enabled new levels of resolution. Here I review eleven breakthrough 
studies detecting eQTL in human samples, highlighting the main results. All of the studies 
support the conclusion that genetic components account for a substantial proportion of gene 
expression variation in humans, and allow me to extrapolate some trends to be expected in 
human eQTL studies in the coming years.  
 
1. In the year that the idea of eQTL was proposed, the first eQTL linkage study in 
yeast was published (Brem et al. 2002). In this study, the genetic basis of expression 
differences between two strains was explored for 6,215 genes, and although only one 
quarter of the genes were found to be under overall genetic control, 570 genes were 
regulated by at least one eQTL. Furthermore, a dozen hot-spots regulating many genes in 
a trans-manner were described.  Results from this study clearly revealed that at the 
transcriptome level, gene expression is globally regulated by genetic variants.  
2. The first study in humans to explore local genetic contributions to gene 
expression variation was conducted in LCL with the CEPH family data (Yan et al. 2002). 
These are pedigrees of European-ancestry living in Utah with grandparents, parents, and 
Figure 1.2 Breakthrough eQTL studies in human tissues 
 9 
up to eight children. Yan et al focused on 13 target genes for which 17-37 heterozygous 
individuals were available, and measured the relative expression of two alleles in the same 
individual. Their results showed significant differences in allelic variation for 6 of the 13 
genes, revealing expression patterns in humans consistent with Mendelian inheritance, and 
anticipating later allele-specific expression (ASE) research.  
3. In 2003, Schadt et al. performed a comparative analysis of gene expression 
genetics in mouse, maize and human (Schadt et al. 2003). Linkage analysis was performed 
to detect eQTL for 23,574 transcripts measured in livers of 111 mice from the F2 generation 
of a laboratory cross, and approximately 100 microsatellite markers were used to discover 
that 9-16% of the explored genes have eQTLs with LOD scores > 4.3. Similarly, eQTL 
analysis of the maize ear leaf identified 26% of transcripts harboring ≥ 1 eQTL with a LOD 
score > 3.0. Although genotypic data was lacking, Schadt et al. also studied a small number 
of human LCLs of 56 subjects through variance components analysis and identified 
differential expression for 11% of the genes assayed, of which about a third had detectable 
heritability. Overall, these findings provided the first hint of the complexity of the genetic 
architecture of gene expression across species.  
4. Up to this point, human eQTL studies had been performed with only limited 
genetic markers (≤1000), and were mainly based on linkage analysis. Cheung et al carried 
out association analysis with dense sets of single-nucleotide polymorphism (SNP) markers 
from the HapMap Project. For 27 of 374 molecular phenotypes, analysis of genome-wide 
association was performed with >770,000 SNPs. The association analysis confirmed 
previous results from linkage studies, and narrowed down the candidate regions, greatly 
increasing the fine-mapping resolution (Cheung et al. 2005).  
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5. To explore the characteristics of gene regulation in different human populations, 
Stranger et al. (Stranger et al. 2007b), investigated LCL from four populations in the 
HapMap project: 30 Caucasian (CEU) trios, 30 Yoruba (YRI) trios from Nigeria, 45 
unrelated Chinese (CHB) and 45 unrelated Japanese (JPT). Analysis of 14,456 transcripts 
revealed that 10% and 13% of molecular phenotypes in CEU and YRI had heritability           
> 0.2, respectively, and 958 of the eQTL were discovered in both populations. Furthermore, 
6% of explored transcripts had significant eQTLs in at least 1 population at p < 0.001; 2% 
in at least two populations, and 0.4% in all four populations. In order to further characterize 
the population specificity of gene expression regulation, Spielman et al compared gene 
expression in three major population groups, and found that at least 25% of the gene were 
differentially expressed among populations (Spielman et al. 2007), although this result was 
later found to be largely confounded by batch effect, so the divergence estimate had been 
much inflated (Akey et al. 2007). Idaghdour et al evaluated the eQTL regulation in whole 
blood from Arab and Amazigh, and found that most of the eQTLs had consistent signals, 
verifying the shared cis-genetic influences on gene regulation (Idaghdour et al. 2010b). 
Despite the small sample size, these eQTL results coherently demonstrated the sharing of 
genetic factors in gene expression regulation across different human populations.  
6. Revealing the genetic component of gene expression across human tissues, 
Grundberg et al (2012) presented a comprehensive analysis of gene expression in LCL, 
skin, and adipose.  They calculated heritability and evaluated the genetic and non-genetic 
contributions to expression with a large sample of mono- and dizygotic twins, concluding 
that at least 40% of the total heritable cis effect on expression may originate from rare 
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variants, while a substantial proportion of gene expression heritability must be due to trans-
acting genetic factors. 
7. In contrast to previous eQTL studies mainly exploring contributions of SNPs, 
Stranger et al investigated the effects of another type of genetic variation, copy number 
variants (CNVs), on gene expression levels. They performed association for 14,925 
transcripts with CNVs in the HapMap populations and determined that there were 
significant CNV associations that replicate across ethnic groups as well as some that are 
unique to single populations (Stranger et al. 2007a). Most CNV associations were 
independent of proximal SNPs, highlighting the importance of structural variants in 
addition to SNPs in the regulation of gene expression.  
8. Recently, several groups have begun to investigate the genetic basis for 
differences among individuals in gene expression in different contexts, such as the immune 
response to stimulation.  These effects have been termed response-eQTL, and were first 
explored in the nematode, Caenorhabditis elegans (Li et al. 2006).  The first human 
response-eQTL study described by Lee et al using dendritic cells (DCs) derived from 
monocytes of healthy individuals, with 295 Caucasians, 122 African Americans, 117 East 
Asians.  The DC were stimulated ex vivo with lipopolysaccharide (LPS), influenza virus, 
or the cytokine interferon-β (IFN-β) (Lee et al. 2014). Common variants were genotyped 
and correlated with gene expression from each condition, and then synthetic promoter 
constructs and genome engineering were applied to experimentally confirm some of the 
detected associations. A nanostring array was used to measure 1,598 molecular 
phenotypes, of which 264 were shown to be regulated by genetic variants associated with 
gene expression in human DCs.  Signals from 121 of the loci were uniquely influenced by 
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stimuli. Co-localization analysis also revealed that 35 of the eQTLs were likely to affect 
autoimmune phenotypes through alteration of gene expression. 
9. Most large human eQTL studies have been performed with healthy subjects 
rather than directly in the context of disease.  Ongen et al conducted an RNA-sequencing 
experiment involving 103 matched tumor and normal colon mucosa samples from Danish 
colorectal cancer (CRC) patients, of which 90 were germline-genotyped (Ongen et al. 
2014). Correlation of genotypes with gene expression found 1,693 and 948 eQTLs in 
normal samples and tumor samples, respectively. They estimated that 36% of the tumor 
eQTLs are cancer-specific, partially driven by altered expression of specific transcription 
factors and changes in methylation patterns. The authors also found that tumor-specific 
eQTLs were more enriched for low CRC genome-wide association study (GWAS) P values 
than shared eQTLs, which implies that some of the GWAS variants are tumor specific 
regulatory variants. Importantly, compared to genes with shared eQTLs, genes with tumor-
specific eQTL tended to accumulate more allele-specific expression, indicating that 
somatically-derived mutations may constitute cancer regulatory drivers.  
10.  To assign the contribution of cis- and trans-eQTL to overall expression 
variance, Lloyd-Jones et al analyzed the mRNA levels for 36,778 probes in 2,765 
individuals, and investigated the genetic architecture of gene expression in peripheral blood 
(Lloyd-Jones et al. 2017). 11,204 cis and 3,791 trans independent expression quantitative 
trait loci (eQTL) were detected. For expressed probes (15,966), 66% had a non-zero 
narrow-sense heritability, the mean estimate of which was 0.192, 31% of which was 
assigned to detected eSNPs, while 69% remained missing. The evidences suggests that 
approximately half the genetic variance for gene expression is not tagged by common 
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SNPs, possibly indicating a crucial role for rare variants on gene expression.  This also has 
implications for the likely evolutionary origin of the variance that is tagged by common 
SNPs, a large proportion of which can be attributed to identifiable eQTL of large effect, 
typically located in cis. Limited by the small statistical power and great burden of multiple 
test correction, trans-eQTL analysis remains challenging. Westra et al (2013) performed 
expression quantitative trait locus (eQTL) meta-analysis in 5,311 individuals with 
replication in 2,775 individuals. 233 were SNPs associated with complex traits from 103 
independent loci and replicated as trans-eQTL.  Among these trans effects, an excess of 
variants associated with cholesterol metabolism and type 1 diabetes were found to alter the 
expression of multiple genes known to be associated with traits, revealing likely regulatory 
mechanisms for the downstream effect of many trait-associated variants. 
11.  Limited by the availability of tissues from humans, most studies have explored 
only two or three, if not a single, tissue. To have a broader understanding of transcriptome 
regulation across human tissues, and to elucidate the functional consequences of genetic 
variation associated with complex human disease and quantitative traits, the Genotype-
Tissue Expression (GTEx) project was launched. Ardlie et al. (2015) presented the first 
analysis of RNA sequencing data from 1641 samples derived from 43 biopsy tissues from 
175 recently deceased individuals. In this analysis, it was found that an average of 20,940 
genes were expressed in the explored tissues, highest in testis and lowest in whole blood. 
A U-shaped distribution of the number of tissues expressing each gene was observed, 
meaning that most genes are expressed either in most or just a few tissues.  eQTL analysis 
was performed on 9 tissues with largest sample size.  A total of 10,130 eQTLs were 
detected, 50% of which were shared by all of the 9 tissues, showing high concordance of 
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effect directions. The detected eQTLs were enriched for trait associations, many taking 
function in a tissue-dependent manner. Co-localization analysis demonstrated that ~6% 
GWAS-SNPs were in the same LD block as the detected eSNP, suggesting that their 
influence on the trait is mediated through the eQTL effect. 
Table 1.1. eQTL studies in human tissues since 2004. 
Cohort Tissue Year Sample size Reference Note 
CEPH blood 2004 210 Monk et al(MONKS et al. 2004) 346 markers explored 
CEPH LCL 2004 94 Morley et al(MORLEY et al. 2004) 2,756 autosomal SNPs 
CEPH LCL 2005 57 Cheung et al(CHEUNG et al. 2005) 
 
Hapmap LCL 2005 60 Stranger et al(STRANGER et al. 2005) 
 
Hapmap LCL 2007 238 Stranger et al(STRANGER et al. 2007a) 
 
Hapmap LCL 2007 270 Stranger et al(STRANGER et al. 2007b) 
 
SAFHS LCL 2007 1,280 Göring et al(GÖRING et al. 2007) 
 
Hapmap_CEU LCL 2007 30 Stranger et al(STRANGER et al. 2007b) 
 
Hapmap_CHB LCL 2007 45 Stranger et al(STRANGER et al. 2007b) 
 
Hapmap_JPT LCL 2007 45 Stranger et al(STRANGER et al. 2007b) 
 
Hapmap_YRI LCL 2007 30 Stranger et al(STRANGER et al. 2007b) 
 
BR Brain_Cortex 2007 193 Myers et al(MYERS et al. 2007) 
 
SIGN LCL 2007 206 Dixon et al(DIXON et al. 2007) 
 




adipose 2008 673/1002 Emilsson et al(EMILSSON et al. 2008) 
 
Hapmap LCL 2008 269 Choy et al(CHOY et al. 2008) 
 
Hapmap_CEU/YRI LCL 2008 209 Price et al(PRICE et al. 2008) 
 
LV Liver Cell 2008 427 Schadt et a(SCHADT et al. 2008) 
 
Hapmap_CEU LCL 2008 60 Duan et al(DUAN et al. 2008) 
 
Hapmap_YRI LCL 2008 69 Duan et al(DUAN et al. 2008) 
 
InChianti blood 2009 705 Tanake et al(TANAKA et al. 2009) 
 
LOAD Brain 2009 765  Webster et al(WEBSTER et al. 2009) 
 
3C LCL 2009 75 Dimas et al(DIMAS et al. 2009a) 
 
3C Fibroblast 2009 75 Dimas et al(DIMAS et al. 2009a) 
 
3C T_cell 2009 75 Dimas et al(DIMAS et al. 2009a) 
 
Morocco blood 2010 203 Idaghdour et al(IDAGHDOUR et al. 2010a) 
 
DILGOM blood 2010 631 Inouye et al(INOUYE et al. 2010) 
 
Hapmap LCL 2010 69 Pickrell et al(PICKRELL et al. 2010) 
 
GHS  Monocyte 2010 1490 Zeller et al(ZELLER et al. 2010) 
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Hapmap_CEU LCL 2010 60 Montgomery et al(MONTGOMERY et al. 2010) 
 
Hapmap_YRI LCL 2010 69 Pickrell et al(PICKRELL et al. 2010) 
 
BR2 Cerebellum 2010 150 Gibbs et al(GIBBS et al. 2010) 
 
BR2 Frontal_cortex 2010 150 Gibbs et al(GIBBS et al. 2010) 
 
BR2 Temporal_cortex 2010 150 Gibbs et al(GIBBS et al. 2010) 
 
BR2 Pons 2010 150 Gibbs et al(GIBBS et al. 2010) 
 
Psoriatic Skin 2010 57 Ding et al(DING et al. 2010) 
 
 
Liver 2010 960 Musunuru et al(MUSUNURU et al. 2010) rs12740374 
 
Subcutaneous fat 2010 433 Musunuru et al(MUSUNURU et al. 2010) rs12740374 
 
Omental fat 2010 520 Musunuru et al(MUSUNURU et al. 2010) rs12740374 
Fehrmann blood 2011 1469 Fehrmann et al(FEHRMANN et al. 2011) 
 
LV2 Liver cell 2011 266 Innocenti et al(INNOCENTI et al. 2011) 
 
 
trabecular bone 2011 113 Grundberg et al(GRUNDBERG et al. 2011) 
 
 
Liver 2011 266  Innocenti et al(INNOCENTI et al. 2011) 
 
 
brain 2011 269 Colantuoni et al(COLANTUONI et al. 2011) 
 
SHIP-Trend blood 2012 653 Mehta et al(MEHTA et al. 2013) 
 
BSGS blood 2012 962 Powell et al(POWELL et al. 2012) 
 
IM Monocyte 2012 288 Fairfax et al(FAIRFAX et al. 2012) 
 
IM B_cell 2012 288 Fairfax et al(FAIRFAX et al. 2012) 
 
MuTHER LCL 2012 160/856 Grundberg et al(GRUNDBERG et al. 2012) 
 
MuTHER Skin 2012 160/856 Grundberg et al(GRUNDBERG et al. 2012) 
 
MuTHER Adipose 2012 160/856 Grundberg et al(GRUNDBERG et al. 2012) 
 
 
Lung 2012 1111 Hao et al(HAO et al. 2012) 
 
 
Cortex, cerebellum 2012 400 Zou et al(ZOU et al. 2012) 
 
Rotterdam blood 2013 881 Hofman et al(HOFMAN et al. 2013) 
 
EGCUT blood 2013 734 Metspalu et al 
 
KORA F3/F4 blood 2013 322/740 Mehta et al(MEHTA et al. 2013) 
 
GEUVADIS LCL 2013 462 Lappalainen et al(LAPPALAINEN et al. 2013) 
 
MRCA, MRCE LCL 2013 405/950 Liang  et al(LIANG et al. 2013) 
 
E-GEUV LCL 2013 373 Lappalainen et al(LAPPALAINEN et al. 2013) 
 
E-GEUV LCL 2013 89 Lappalainen et al(LAPPALAINEN et al. 2013) 
 
Cardiology blood 2014 338 Kim et al(KIM et al. 2014) 
 
Bangladeshi blood 2014 1800 Pierce et al(PIERCE et al. 2014) 
 
CHDWB blood 2014 189 Preininger et al(PREININGER et al. 2013) 
 
SIGN blood/neutrophil 2014 114 Andiappan et al(ANDIAPPAN et al. 2015) 
 
ALSPAC blood 2014 869 Bryois et al(BRYOIS et al. 2014) 
 
NTR-NESDA blood 2014 2752 Wright et al(WRIGHT et al. 2014) 
 
BLD  blood 2014 1387 Tigchelaar et al(TIGCHELAAR et al. 2015) 
 
DGN blood 2014 922 Battle et al(BATTLE et al. 2014) 
 
ImmVar CD4+ 2014 407 Raj et al(RAJ et al. 2014a) 
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by IFN-b 2014 534 Lee et al(LEE et al. 2014) 
 
ImmVar CD4+  4h α328 2014 348 Ye et al(YE et al. 2014) 236 gene explored 
ImmVar CD4+  48h α328 2014 348 Ye et al(YE et al. 2014) 
 
ImmVar CD4+  4h IFNβ 2014 348 Ye et al(YE et al. 2014) 
 
ImmVar 
CD4+  48h IL-6, 
TGFβ 2014 348 Ye et al(YE et al. 2014) 
 
 
colorectal cancer  2014 103  Ongen et al(ONGEN et al. 2014) 
 
 
breast cancer 2014 415/407 Li et al(LI et al. 2013) 
 
HGVD blood 2014 298 Narahara et al(NARAHARA et al. 2014) 
 
 
Dendritic Cell 2014 534 Lee et al(LEE et al. 2014) 1598 transcriptional profile 
 
Stimulated 
monocytes 2014 432 Fairfax et al(FAIRFAX et al. 2014) 
 
 
Heart 2014 129 Koopmann et al(KOOPMANN et al. 2014) 
 
 
10 brian regions 2014 134 Ramasamy et al(RAMASAMY et al. 2014) 
 
 
skeletal muscle  2014 45 Lindholm et al(LINDHOLM et al. 2014) 
 
 
islets 2014 89 Fadista et al(FADISTA et al. 2014) 
 
PRAX1 platelet 2014 154 Simon et al(SIMON et al. 2014) 
 
YoungFinns blood 2015 1428 Turpeinen et al(TURPEINEN et al. 2015) 
 
LIFE blood 2015 2107 Burkhardt et al(BURKHARDT et al. 2015) 
 
Framingham blood 2015 5626 Huan et al(HUAN et al. 2015) 
 
GTEX blood/other tissue 2015 420 GTEx Consortium(CONSORTIUM 2015a) 
 
 
prostate 2015 565 Thibodeau et al(THIBODEAU et al. 2015) 
 
CartaGene blood 2015 521 Hussin et al(HUSSIN et al. 2015) 
 
 
Islets  2015 118 Bunt et al(VAN DE BUNT et al. 2015) 
 
 
6 immune cell type 2015 91/46/43 Peters et al(PETERS et al. 2016) 
 
 
skeletal muscle  2016 267 Scott et al(SCOTT et al. 2016) 
 
TwinsUK LCL/adipose/skin 2016 845 Hore et al(HORE et al. 2016) 
 
 
macrophage 2016 168 Nédélec et al(NÉDÉLEC et al. 2016) 
 
 
Monocyte  2016 200 Quach et al(QUACH et al. 2016) 
 
 
Whole blood 2016 377 Walsh et al(WALSH et al. 2016) 
 
 
LCL 2016 786 Peterson et al(PETERSON et al. 2016) 
 
METSIM Adipose  2017 770 Civelek et al(CIVELEK et al. 2017) 
 
  CD4+/CD8+ 2017 293/283 Kasela et al(KASELA et al. 2017)   
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1.4 Interpretation of eQTL 
The primary detection of eQTL is methodologically straightforward: gene 
expression is measured from hundreds of individuals usually by microarray or RNA-seq, 
genotypes are obtained and imputed by reference to an appropriate population of known 
haplotypes, and then statistical analysis, either association or linkage studies, are conducted 
to evaluate the relationship between the variance of phenotype (expression) and the 
identities of the genotypes. For a given statistical confidence interval, either based on 
conservative Bonferroni adjustment or at a False Discovery Rate threshold, a variant is 
determined to be associated with the phenotype (Figure 1). However, the interpretation of 
eQTL results is generally not so simple. In biology, a cis eQTL is usually expected to be a 
regulatory element that contributes to gene expression, while, for real data, what is 
discovered is just an interval on the chromosome within which it is inferred that a causal 
variant exists. Because of the existence of extensive LD structure in human populations, it 
is hard to distinguish which variant is causal, or whether or not there are multiple causal 
variants in a single region.  It should be appreciated that eQTL performs association 
analysis, and association doesn’t always imply causality. Additionally, whole blood, the 
most widely used tissue, is actually a mixture of various cell types, and the estimation of 
cell-type-specific eQTL is unavoidably highly biased. 
The general and parsimonious assumption is that functional variants are sparsely 
distributed, and hence that their precise localization or estimation of effect sizes is not 
affected by interference due to confounding of statistical signals.  However, as genome-
wide association studies have increased in size it has become clear that multi-site effects 
are not uncommon.  For example, the latest meta-analysis of height suggests that over one 
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third of the more than 400 identified loci have multiple independent signals (Wood et al. 
2014), and similarly in the transcriptome literature, the expression of a large proportion of 
genes in lymphocyte cell lines has been shown to be regulated by two or more locally-
acting variants (cis-eQTL) (Liang et al. 2013).  Gusev et al (Gusev et al. 2013) observed 
that all SNPs at known GWAS loci can explain 1.29-fold more heritability than GWAS-
associated SNPs on average, and Lloyd-Jones et al (2017) revealed that in peripheral blood 
~23% transcripts are regulated by multiple independent eQTLs. The same situation exists 
in eQTL analysis as well, and lies behind the strategy of predicting gene expression from 
all SNPs within 1 Mb of each gene (Mancuso et al. 2017). Thus, determining the effect of 
these multiple variant SNPs on target transcript levels gives considerably more detail 
concerning the complex regulatory interactions at a locus. Including epigenetic markers 
and enhancer-gene interaction information, Corradin et al (2014) revealed specific cases 
where several variants in LD simultaneously affect gene expression. Applying Bayesian 
methods and incorporating genomic annotations, Wen et al (2015) identified multiple cis-
eQTL signals for ~12% genes with eSNP. Since linkage disequilibrium within a locus can 
be extensive, the potential for mis-estimation of eQTL effects due to interference between 
signals from tightly linked polymorphisms is high. 
Researchers have also found enrichment for cell type-specific eQTLs among 
disease susceptibility alleles. Dimas et al (2009b) detected 69 to 80% of regulatory variants 
operating in a cell type–specific manner. Raj et al found ~40% eQTL functioning in a cell-
specific manner, and documented over-representation of T cell–specific eQTLs among 
susceptibility alleles for autoimmune diseases and of monocyte-specific eQTLs among 
Alzheimer’s and Parkinson’s disease variants (Raj et al. 2014b). Using gene expression as 
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a proxy for cell count percentage, Westra et al (2015) inferred cell-type specific effects 
from whole blood data, also demonstrating that SNPs associated with Crohn’s disease 
preferentially affect gene expression within neutrophils.  
1.5 Interpreting GWAS with eQTL results 
Since the first GWAS results were published in 2005 (Klein et al. 2005), several 
thousand genetic regions on human chromosomes have been found to be associated with 
human phenotypes including disease states. Since it is now assumed that the majority of 
SNP-trait associations identified by GWAS can be attributed to effects on gene expression, 
precise estimation of the location and effect sizes of regulatory polymorphisms has become 
important for understanding the relationship between genetic and phenotypic variation 
(Maurano et al. 2012a; Farh et al. 2015).  Expression quantitative trait locus analysis and 
related functional genomic strategies are thus now a standard component of genetic fine 
mapping (Nicolae et al. 2010).  The minimal expectation is that they can identify the gene 
within a locus that accounts for a GWAS signal, although even this is a far from trivial 
undertaking (Chung et al. 2014; Pickrell 2014).  Many investigators make the stronger 
assumption that co-localization of eSNP and GWAS signals to a tight linkage 
disequilibrium interval implies the ability to define if not the causal variant, then at least a 
credible set of SNPs that include the causal site (Trynka et al. 2013; Gaulton et al. 2015; 
Kichaev and Pasaniuc 2015; Liu et al. 2015).  The strong enrichment of chromatin marks 
such as DNAse Hypersensitive Sites (DHS) in the vicinity of eQTL validates this 
assumption (ENCODE Consortium, 2012; Roadmap Epigenomics Consortium, 2015). 
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Table 1.2. Experimentally verified GWAS hits 
Disease/Trait study Gene eQTL tissue Reference 
Asthma ORMDL3 YES LCL Moffatt et al, 2007(MOFFATT et al. 2007) 
Blood lipid level SORT1 YES Liver Musunuru et al, 2010(MUSUNURU et al. 2010) 
Blood lipid level PPP1R3B YES Liver Teslovich et al, 2010(TESLOVICH et al. 2010) 
Blood lipid level TTC39B YES Liver Teslovich et al, 2010(TESLOVICH et al. 2010) 
Breast cancer RRP1B YES PyMT-induced primary tumours Crawford et al, 2007(CRAWFORD et al. 2007) 
Chronic lymphatic 
leukaemia ASPM UNKNOWN 
 
Horvath et al, 2006(HORVATH et al. 2006) 
ventricular 
conduction system SCN10A UNKNOWN 
 
Sotoodehnia et al, 2010(SOTOODEHNIA et al. 2010) 
Parkinson SNCA YES Postmortem frontal cortex Soldne et al, 2016(SOLDNER et al. 2016) 
T2D IRX3/IRX5 YES Adipocyte Claussnitzer et al, 2015(CLAUSSNITZER et al. 2015) 
However, high resolution fine mapping eQTL results aligned with GWAS studies 
for diverse phenotypes has as yet provided only a few instance of site-specific evidence 
that variants affecting human complex traits and diseases function through their effect on 
gene expression. Table 1.2 lists nine experimentally verified GWAS hits which have been 
validated to affect the phenotype. There are two prominent examples. The first one is a 
common SNP at 1p13, a locus associated with the risk of myocardial infarction (Musunuru 
et al. 2010).  This SNP is found to be located in the 3ʹ untranslated region of a gene, and 
the minor allele creates a binding site for a transcription factor (TF) that is preferentially 
expressed in the liver, as a consequence of which, the target gene sortilin 1 (SORT1) is 
upregulated specifically in the liver. Knockdown studies in mouse liver confirmed that 
higher expression of the sortilin protein results in lower levels of low-density lipoprotein 
cholesterol (LDL-C), which is associated with higher risk of myocardial infarction. The 
second example is the SNCA gene. Using the CRISPR/Cas9 genome editing method, 
Soldner et al (2016) identified a common Parkinson’s disease (PD)-associated risk variant 
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in a non-coding distal enhancer element that regulates the expression of alpha-synuclein 
(SNCA), a key gene implicated in the pathogenesis of PD. The results suggest that the 
transcriptional deregulation of SNCA is associated with sequence-dependent binding of a 
brain-specific TF. Both of these GWAS hits were found to be associated with gene 
expression, and affect TF binding ability, which complies with biological expectations. 
On the other hand, several recent studies have begun to question the presumed 
identity of eQTL and GWAS hits: even though there is a highly significant overlap at the 
level of the locus (Maurano et al. 2012), it is not so clear that the precise variants are the 
same.   Farh et al (2015) integrated regulatory elements and GWAS results, and estimated 
that only ~10% of the GWAS hits function as eQTL, and a more recent comprehensive 
study of autoimmune disease also argued that only one quarter of examined GWAS loci 
may act as discovered eQTL (Chun et al. 2017). Similarly, work based on GTEx gene 
expression aiming to integrate GWAS and eQTL results concluded that only a minority of 
GWAS loci match eQTL (Hormozdiari et al. 2016). These results from statistical analysis 
raise the question of why there are so many instances of discordant fine localization: are 
we simply limited by the low statistical power to detect association signals (Udler et al. 
2010); is there mis-estimation of signal strength and location in the case of multiple eQTL 
per transcript; or are regulatory effects so cell-type and context-specific that true co-
localization is often missed?  From the opposite perspective, regulatory sites may often be 
selectively neutral due to small probability of affecting phenotypes, and hence do not 
appearing in low-powered GWAS scans. 
1.6 Constraints on fine-mapping resolution due to LD 
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Linkage disequilibrium (LD) is a phenomenon whereby alleles at closely linked 
sites tend to be inherited together (Pritchard and Przeworski 2001). Several evolutionary 
factors, including demography, population structure, recombination, mutation, and natural 
selection, create, shape and modify the rate of decay of LD. Consider two loci, A and B, in 
an ancestral population, where site A is a bi-allelic variant, with M and m are the major 
and minor allele, respectively, and there is only a single allele N for B. At some specific 
time or place, a mutation happens in site B in a person with M in site A, and this allele 
spreads into the population.  Initially the new site n is only found on the M chromosome, 
so there is complete LD between M and n.  As time goes by, recombination occurs, forming 
the haplotype with m and n.  Eventually, n is just as likely to be on the M and the m 
chromosomes, at which point linkage equilibrium is reached.  Also, admixture between 
two populations creates temporary LD at loci throughout the genome.  By definition, a 
straightforward method to measure the LD strength is to evaluate D = PMPN-PMN, where 
PM is the allele frequency of allele M in site A, and PN the allele frequency of allele N in 
site B, PMN, the haplotype frequency of MN. In the case of linkage equilibrium, alleles in 
different loci segregate randomly, resulting in PMN = PMPN, and D=0. In the presence of 
LD, D does not equal zero. Since D calculated with the above formula has the disadvantage 
that it is largely affected by allele frequencies, making it difficult to compare the level of 
linkage disequilibrium between different pairs of loci, two alternative measures of LD have 
been devised to correct this: D’ and r2. D’ is a normalized D divided by the theoretical 
maximum difference between the observed and expected allele frequencies as follows: D’= 
D/Dmin, Dmin=max(-PMPN, -(1-PM)(1-PN)), when D<0, and Dmin=min(PM(1-PN), (1-PM)PN), 
when D>0. Before recombination, D’ is always 1, and in the presence of recombination, 
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D’ decays gradually. An alternative to D' is the correlation coefficient between pairs of 
loci, r=D/sqrt(PM(1-PM)PN(1-PN)) (Hill and Robertson 1968). 
In the human genetics field, the Out of Africa hypothesis is the most prominent 
model used to explain the evolutionary history of anatomically modern humans. According 
to this model, modern humans dispersed from East Africa to the Eurasian landmass and 
other continents starting 100,000~60,000 years ago (Mellars 2006; Mallick et al. 2016). 
Consequently, populations of European- and Asian-ancestry are much younger than 
African ones.  There has been less time to break down LD resulting from sub-sampling of 
a fraction of human diversity during the population bottleneck that occurred during 
dispersal. Consequently, Europeans and Asians tend to have longer segments of LD than 
Africans, and non-causal variants typically locate in long LD blocks along with causal 
ones. Consider the scenario where a causal variant, C, affects a continuous phenotype, and 
assume a minor allele frequency PC, and allelic effect size βC. When performing an 
association study to evaluate the relationship between each genetic variant and the 
phenotype, for non-causal variants in LD with a causal variant, the effect size estimate is 
β̇=r* βC, where r is the correlation coefficient between causal and non-causal variants. In 
the presence of extensive LD in the study population, r tends to be large for tens to hundreds 
of linked sites, and consequently estimation for causal and non-causal variants is similar, 
greatly reducing fine-mapping resolution. Even more disturbing, when multiple causal 
variants exist, interference between these variants will bias the estimation. Considering 
another scenario, where two causal variants affect the phenotype together, estimation for 
any variant will be β̇= r1* βC1+ r2*βC2, where r1 is the genotypic correlation of the explored 
variant to causal variant 1, and r2 to causal variant 2. When the causal variants function in 
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opposing directions, there is a strong chance that β̇ equals or is near to 0, which means the 
causal variant will be mis-labelled as non-causal.  When the causal variants function in the 
same direction, it is possible that  β̇ for the non-causal site is greater than the true βc for 
either causal site, and the incorrect inference will be made that there is a single eSNP, 
whose location and effect size will be mis-specified. 
1.7 Comparison of Frequentist and Bayesian tools for eQTL estimation 
Assuming that multiple eQTL contribute to expression variance at a locus, diverse 
methods have been developed to detect multiple independent eQTLs. Conditional analysis 
is the most widely used method to detect independent signals in GWAS (Yang et al. 2012). 
It performs step-wise detection, namely, the novel signal is found conditioning on the 
effects of previously detected signals. In the scenario that multiple causal variants locate 
in different LD blocks, conditional analysis selects one variant as a tag for each LD block. 
In contrast, Bayesian-based methods are designed to perform association and fine-mapping 
simultaneously. In the Bayesian framework, to select variables as causal, the approach is 
to comprehensively survey the causal status space under a set of prior assumptions, and 
then use posterior probability values to evaluate the importance of each combination of 
variants. Several Bayesian methods have been developed, and there are two categories: one 
is used when individual genotype and phenotype are available, and the other one is applied 
when only marginal summary results are available. FMQTL (Wen et al. 2015) and DAP 
(Wen et al. 2016) use each individual’s genotype and phenotype to detect multiple eQTL. 
FMQTL applies the Metropolis Hasting algorithm in the MCMC method to sample the 
causal states, and calculates a posterior inclusion probability from the marginal sampled 
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causal states. To reduce the computational burden, Wen et al developed DAP, in which 
only the causal status associated with high-probability variants were explored instead of 
sampling. Another package, CAVIAR (Hormozdiari et al. 2014), was developed to deal 
with summary statistics. In CAVIAR, the marginal statistical association results and LD 
structure are used to explore the probability of each causal status. CAVIAR-BF (Chen et 
al. 2015), PAINTOR (Kichaev et al. 2014), and FINEMAP (Benner et al. 2016) were 
developed with similar logical models. One disadvantage of most of these Bayesian 
methods is that they output a list of SNPs with a specific confidence that causal variants 
are included or a set of causal statuses with high probability, but there is no estimation for 
the parameters of the underlying causal variants, such as effect size betas. To estimate these 
parameters, we need to choose the causal status with the largest probability, and perform 
multiple-variable regression to estimate the allelic effect sizes. 
In this thesis, I first describe simulation studies which reveal that in the scenario of 
multiple eQTL regulation, interference between causal variants results in greatly biased 
estimation, and then develop a statistical model to identify multiple regulatory variants 
affecting gene expression, combining both frequentist and Bayesian methods. To integrate 
eQTL signal to interpret GWAS results, I then develop a new joint mapping method to 
evaluate the co-localization of eQTL-GWAS signal, and use it to identify causal genes and 
causal variants for human complex traits and disease. In addition, as a member of Prof 
Lude Franke’s eQTLgen consortium (University of Groningen, The Netherlands), I also 




1.8 Thesis Structure 
Specific Aims:     Statistical Dissection of the Regulation of Gene Expression and its 
application in interpretation of GWAS findings 
In this thesis, on the assumption that multiple regulatory variants are present per 
locus, I conduct a systematic evaluation of whether and how transcription is affected by 
combinations of SNPs in two or more regulatory intervals.  Based on the resultant 
regulatory signals, I then describe how to use this information to interpret GWAS results, 
and reveal potential biological mechanisms. My approach is to perform a Bayesian 
statistical assessment of causal variants and causal genes for human complex phenotypes 
and disease states. Two large eQTL datasets have been analyzed in order to develop 
statistical methods that control for population and family structure, and perform 
simultaneous multi-site eQTL detection in the presence of variable levels of linkage 
disequilibrium. With the available ~1,300 GWAS summary results, I also conducted co-
localization analysis to evaluate the potential causal variants, and causal genes. 
Aim 1. Establish limits to fine-mapping imposed by interference among linked sites 
at a single locus. 
The first objective of my thesis was to explore sources of error in estimating joint 
eQTL effects. Empirical analysis of the CAGE dataset of 2,800 whole blood profiles 
generated statistical evidence that 2, 3 or even more sites regulate the expression of a gene 
is common.  I used simulations to explore the effect of untagged variants and multi-site 
regulation on the localization of, and effect size estimation of, statistical peaks. I also 
showed that under plausible parameters there is a non-trivial likelihood that discovered 
eQTL credible intervals do not actually include the causal variant. To reveal the limitations 
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of current frequentist and Bayesian methods, I then performed simulations to compare 
sequential conditional and Bayesian joint mapping methods for eQTL detection in 
scenarios where multiple eQTL regulation is prevalent, and compared the advantages and 
pitfalls of the two methods. 
Aim 2. Development of a novel pipeline, PolyQTL, for fine mapping eQTL effects. 
In Aim 1, it became apparent that conditional mapping is fast and efficient for 
detection of independent eQTL in low LD, while the Bayesian methods are more 
computationally demanding but have increased resolution of multiple eQTL within high 
LD blocks.  In this Aim I present a new pipeline, PolyQTL, which combines the two 
approaches while also accounting for population and pedigree structure and can incorporate 
functional and evolutionary information into the fine mapping. The method was applied to 
contrast multi-eQTL profiles in the CAGE and Framingham Heart Study (FHS) whole 
blood datasets.  The results indicate that the Illumina and Affymetrix platforms yield 
similar numbers of eQTL, but have very different fine mapping results for more than half 
of all expressed genes.  I discuss the reasons for the discrepancy, and have generated a 
public database that provides joint mapping profiles and summary statistics suitable for co-
localization studies.   
Aim 3. Application of eQTL to interpret GWAS results. 
Since in previous studies, only a limited proportion of GWAS hits were 
demonstrated to influence traits through gene expression, I inferred that there are two major 
limitations: first, the assumption of single-causal variant in one locus may not hold since 
there are multiple local causal variants influencing regulation of the transcript, and second, 
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sample size.  In this aim, I tested whether additional secondary eQTLs can be used to 
discover novel co-localization signals. I extended the previously developed PolyQTL 
method to evaluate whether or not the eQTL statistical signals overlap with GWAS signals. 
A significant degree of overlap indicates a co-localization, and my method can be used to 
refine both causal variants, and causal genes.   
Aim 4. Trans-eQTL detection in structured populations. 
Although eQTL analysis has become prevalent in human genetics and is widely 
used to interpret GWAS results, most eQTL studies focus only on cis-eQTL effects. The 
detection of trans-eQTL may provide additional, more detailed information regarding gene 
expression networks, and elucidate potential biological mechanisms for the regulation of 
transcript abundance. Dr. Lude Franke launched the eQTLgen Consortium in order to focus 
on trans-eQTL, by applying meta-analysis with more than 30,000 samples collected from 
labs around the world. As a member of this consortium, I was responsible for detection of 
trans-eQTL in the highly family-structured Framingham Heart Study, and for comparison, 
using a pipeline provided by eQTLgen, of results for three cohorts collected in Professor 
Gibson’s lab. In this aim, I provide a detailed description of my method of trans-eQTL 





Interference between causal variants in LD Constrains eQTL 
fine mapping  
ABSTRACT: In this chapter, I explore the interference between causal variants when they 
locate in a region of high linkage disequilibrium. Widely used to interpret genetic risk 
factors associated with disease or clinical phenotypes by GWAS, most of which locate in 
non-coding regions, expression quantitative trait locus (eQTL) detection has emerged as 
an important tool for elucidating detailed biological mechanisms. Most eQTL studies apply 
univariable linear regression to discover primary signals, and then conduct sequential 
conditional modeling to detect additional genetic variants affecting gene expression. 
However, this approach assumes that functional variants are sparsely distributed and that 
close linkage between them has little impact on estimation of their precise location and the 
magnitude of effects. Here, I describe a series of simulation studies designed to evaluate 
the impact of linkage disequilibrium (LD) on the fine mapping of causal variants with 
typical eQTL effect sizes. In the presence of multisite regulation, even though between 80 
and 90% of modeled eSNPs associate with the normally distributed traits, up to 10% of all 
secondary signals could be statistical artifacts, and at least 5% but up to one-quarter of 
credible intervals of SNPs within r2 ≥ 0.8 of the peak may not even include the causal site. 
The Bayesian methods eCAVIAR and DAP (Deterministic Approximation of Posteriors) 
provide only modest improvement in resolution. With the results from simulations, I 
conclude that fine mapping of causal variants needs to be adjusted for multisite influences, 
but ultimately experimental verification of individual effects is needed. Presumably similar 
conclusions apply not just to eQTL mapping, but to multisite influences on fine mapping 
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of most types of quantitative trait loci. Contents in this chapter have already been published 
in the journal G3, as Zeng et al., 2017. 
2.1 Background 
Biological and statistical evidence imply that many SNP-trait associations 
identified from genome-wide association studies can be attributed to effects on gene 
expression.  Consequently, fine-mapping to precisely estimate the effect size and define 
the location of causal variant(s) has become crucial for our understanding of the 
relationship between genetic risk and phenotypic variation (Maurano et al. 2012; Farh et 
al. 2015), and eQTL analysis now has become a standard component for GWAS studies 
(Nicolae et al. 2010). However, investigators tend to expect that it is simple to identify the 
causal genes at each locus, but even this is a far from trivial undertaking (Chung et al. 2014; 
Pickrell 2014). Further, when integrating eQTL signals into the GWAS interpretation, 
many researchers make the stronger assumption that co-localization of eSNP and GWAS 
signals to a tight LD interval implies the ability to define if not the causal variant, then at 
least a credible set of SNPs that include the causal site (Trynka et al. 2013; Gaulton et al. 
2015; Kichaev and Pasaniuc 2015; Liu et al. 2016). Studies across a wide range of 
organisms including yeast, mice, and several plant species, reviewed by Albert and 
Kruglyak (2015) and Cubillos et al. (2012), show that individual regulatory substitutions 
can be experimentally defined and linked to visible phenotypes. Similarly, the SORT1 
example in humans (Musunuru et al. 2010) showed how dissection of the path from 
regulatory variant to tissue-specific expression can define causal influences on (heart) 
disease. However, this is painstaking work that relies on strong prior statistical or 
functional prediction of likely credible intervals. The enrichment of chromatin marks such 
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as DNAse hypersensitive sites in the vicinity of eQTL validates the assumption that many 
credible intervals encompass regulatory SNPs (ENCODE Project Consortium 2012; 
Roadmap Epigenomics Consortium 2015), but conversely raises the question of why there 
are so many instances of discordant fine localization (Huang et al. 2015; Chun et al. 2017); 
does this reflect biochemistry (regulatory sites do not always map to ENCODE elements), 
or simply limits to the statistical resolution of association signals (Udler et al. 2010)? 
It is generally assumed that functional variants are sparsely distributed across 
genomic loci, and that the statistical estimation of effect size and localization isn’t hindered 
by the confounding of statistical signals stemming from LD. However, as GWAS have 
increased in size, it has become clear that multisite effects are not uncommon. For example, 
a recent meta-analysis of height suggests that over one-third of the 400 identified loci have 
multiple independent signals (Wood et al. 2014), and that the expression of a large 
proportion of genes in lymphocyte cell lines is regulated by two or more locally acting 
variants (cis-eQTL) (Liang et al. 2013). Human chromosomes have extensive LD often 
over more than 100kb, and thus the potential for mis-estimation of eQTL effects due to 
interference between signals from tightly linked polymorphisms could be high. In this 
chapter I describe a combination of simulation studies designed to address this concern. 
Heritability analyses have shown that, on average, up to half of the variance of 
phenotypic traits, or of transcript abundance, can be explained by genetic factors, mostly 
acting in an additive manner (Powell et al. 2013; Wright et al. 2014). In contrast to GWAS 
for visible phenotypic traits, in which the identified genetic variants only explain a subtle 
proportion of phenotypic variance (<1%), an important difference in eQTL is that one or a 
few SNPs are often found to explain a large proportion (>10%) of the genetic variance. 
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These variants usually lie within 1 Mb of the transcript and are defined as cis-acting 
regulatory polymorphisms. Expression heritability results by Lloyd-Jones et al. (2017) 
showed that 35% of all expressed genes in peripheral blood have narrow sense heritability 
>0.1, with a median of 0.3, and the primary cis-eQTL, which has the strongest association 
signal at a locus, typically explains 85% of the locally acting variance, which is two-thirds 
of that attributed to all detected eQTL. The majority of the genetic variance is generally 
actually due to trans-acting polymorphisms of small effect.  
The largest blood eQTL study reported to date, assembled from meta-analysis of 
over 5,000 individual Illumina microarray samples (Westra et al. 2013), reported single 
site local associations that are genome-wide significant for 6418 genes (44% of those 
tested) with a 5% false discovery rate. However, the blood eQTL browser only provides 
single site (unconditional) estimates for all local SNPs at each locus. A more powerful 
cross-population Bayesian method (Gusev et al. 2014), applied to just 420 lymphocyte cell 
lines in the Geuvadis dataset (Lappalainen et al. 2013), found a very similar number of 
genes with evidence for regulation by a local eQTL (eGenes), 14% of which had strong 
evidence for secondary association signals in a multisite analysis (Wen et al. 2015). 
One of the major factors constraining our understanding of eQTL regulation is the 
limited availability of human samples. Increased sample size should not only reveal more 
specific instances of multisite regulation, but also provide the opportunity to more 
accurately define effect sizes in the presence of multiple sites that have varying degrees of 
LD. Figure 2.1 illustrates the reasoning for a hypothetical case. Five true eSNP effects are 
indicated by red lines with increasing effects above the horizontal and decreasing below it, 
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while single site unconditional estimates at common variants across the locus are indicated 
as black lines.  
Where two sites in high LD have effects in the opposite direction (green circle), 
they will either cancel each other out or substantially bias the effect size estimates.     Where 
two sites act in the same direction (blue circle), their effects will tend to be added together, 
and hence the strongest association will overestimate the effect while the secondary site 
will be underestimated or not detected. Weaker associations (brown circle) may be 
undetected if they are influenced by even low levels of LD. In theory, if the location of the 
functional sites is known a priori, these difficulties can be resolved by multisite linear 
regression simultaneously fitting all of the identified SNPs. In practice, the identities of the 
functional sites are unknown, and exhaustive multisite modeling is impractical, so 
Figure 2.1 Schematic of multi-site regulation of gene expression.  Black bars indicate 
univariate estimates of allelic effects of minor alleles increasing (above the horizontal) 
or decreasing (below the horizontal) gene expression without conditioning on other 
sites.  Red bars show the actual effects at 5 SNPs in this locus, which has a linkage 
disequilibrium profile with two large and one small block of elevated LD (pink 
squares).  Dotted horizontal lines indicate a statistical significance threshold, which is 
only exceeded in the univariate modeling by the two left-hand sites (blue circle).  Since 
these two sites act in the same direction, they reinforce one another, leading to over-
estimation of their effect sizes, whereas the two at the right (green circle) interfere 
with one another antagonistically, leading to under-estimation of their effects.  The 
effect at the fifth site (brown circle) may only be identified following conditional 
analysis. 
 34 
sequential conditional analyses are used to find secondary, tertiary, and so forth 
associations that are independent of the primary signal. In the presence of strong LD, this 
approach is expected to miss independent associations, which will remain confounded with 
the primary signal. 
Several Bayesian methods have recently been introduced to improve localization 
of linked causal variants. CAVIAR (Hormozdiari et al. 2014) enumerates all possible 
causal states for one or more sites in a short interval of 100 SNPs, but to control the 
computational burden, the maximum number of causal variants is typically set to two. It is 
claimed to improve identification of causal variants by 20%–50% over existing methods 
such as BIMBAM (Servin and Stephens 2007). The eCAVIAR extension for combined 
eQTL and GWAS analysis (Hormozdiari et al. 2016) uses a greedy method to find a subset 
of SNPs with a specific confidence (95% by default) that causal variants are identified as 
candidates. PAINTOR (Kichaev et al. 2014) uses a similar algorithm, whereas FM-QTL 
(Wen et al. 2015) applies an MCMC algorithm to explore the causal status space, utilizing 
a posterior inclusion probability to choose the causal variant credible interval. DAP 
software was then developed (Wen et al. 2016) to explore high probability causal intervals 
with reasonable runtime. FINEMAP (Benner et al. 2016) uses a logical schema that is 
similar to that of CAVIAR, but adopts a Shotgun Stochastic Search method to restrict the 
search space and focus on combinations of high probability intervals. 
In this study, I aimed to explore the sources of error in estimating eQTL effects by 
using simulations to ask how multisite regulation influences (i) the number of independent 
peaks detected by stepwise conditional analysis, (ii) the accuracy of localization of true 
causal variants, and (iii) the effect size estimation of discovered causal variants. I also 
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address the question of what proportion of discovered peaks may be driven by 
undocumented variants in LD with the genotyped sites, and conclude with a comparison of 
the performance of two recently developed Bayesian joint localization methods, eCAVIAR 
and DAP.  Only minor improvements in detection of linked causal variants was obtained, 
and this has little impact on fine mapping, particularly in regions of high LD or if sample 
sizes are small. 
2.2 Material and methods 
2.2.1 Consortium for the Architecture of Gene Expression (CAGE) dataset 
My simulations utilize genotypes obtained from the CAGE dataset, which consists 
of Illumina HT12 microarray-based gene expression profiles, as well as whole-genome 
genotype information from five research studies: the Brisbane Systems Genetics Study 
(BSGS, N = 926) (Powell et al. 2012), the Atlanta-based Centre for Health Discovery and 
Well-Being (N = 439) (Wingo and Gibson 2015) and Emory Cardiology Genebank (N = 
147, Kim et al. 2014), the Estonian Genome Centre, University of Tartu study (N = 1065, 
Schrammet al. 2014), and the Morocco Lifestyle study (N = 188, Idaghdour et al. 2010), 
for a total of 2765 individuals. Since the BSGS sample includes twins, it was removed to 
avoid complications of relatedness, leaving a set of 1839 European- ancestry unrelated 
individuals. IRB approval was obtained for the combination of data into a mega-analysis, 
both by the University of Queensland and for each participating site. 
Genotype imputation for the CAGE cohort was performed jointly on the five 
contributing studies by collaborators at the University of Queensland, to ensure uniformity 
of assignment of strand identities of SNPs. It was described in detail in Lloyd-Jones et al. 
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(2017) and at https://github.com/CNSGenomics/impute-pipe. Briefly, the pipeline 
involved: (1) pre-imputation quality control and data consistency checks; (2) imputation to 
the 1000G reference panel with Impute2 (Howie et al. 2012); (3) post imputation quality 
control (filtering on various data features); and (4) merging datasets on common SNPs. 
2.2.2 Simulation studies  
I conducted four different simulation studies. In all cases, the terminology uni-site 
(univariable) is used to refer to models where a single causal variant is modeled as a fixed 
effect, and multisite (multivariable) where two or more variants are modeled, also as fixed 
effects. The term multi-variate modeling is used for situations where there are two or more 
dependent variables, whereas in these models I assess the joint effects of two or more causal 
variables, hence perform multivariable modeling. Some models also incorporate random 
effects of covariates such as a genetic relationship matrix. 
The first set of simulations assessed the power and accuracy of two site regressions 
assuming that the identities of the two causal variants are already known. I modeled the 
influences of effect size, minor allele frequency (maf), LD, and sample size. Environmental 
variance was randomly generated as a z-score (mean 0 and SD 1) and genotype effects (b) 
were added in SD units (sdu) multiplied by 0, 1, or 2 according to genotype so as to account 
for from 2% to 30% of the phenotypic variance, computed as 2P(1-P)β2. Thus, an allele 
with β = 0.8 is expected to explain 20% of the variance if maf P = 0.2, or 32% of the 
variance if P=0.5.The influence of LD was assessed at r2 = 0.1, 0.5, or 0.9, noting that as 
LD increases, high r2 values are not obtained for combinations of a rare and a common 
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allele. For each combination of parameter values, I generated 1000 randomizations of the 
environmental variance, and assessed (i) the univariate estimate at each genotype, (ii) the 
mean conditional estimate of the second SNP, and (iii) the joint effect estimates with both 
SNPs. From these values, I computed the mean absolute value of the deviation between the 
observed estimate and the true effect size from the univariate, conditional, and joint (two 
site) models. The univariate estimates agree extremely well with expectations from the 
analytical solution described in the Results.  
The second simulation study asked whether unimputed variants influence the 
localization of eSNP signals. Since non-imputed SNPs are not present in the CAGE data, 
I approximated their identities by randomly sampling from a set of CAGE-imputed SNPs 
weighted to have the same frequency distribution shown in Figure 2.3C and assigning 
effect sizes from 2% to 10% of the variance explained for normally distributed pseudogene 
expression traits using the CAGE (without BSGS samples) genotypes. I then removed the 
SNP and all other SNPs with r2 ≥ 0.8, and performed stepwise conditional regression, 
documenting instances of primary and secondary signals at P ≤ 10-5, as plotted in Figure 
2.3E. The cumulative proportion of spurious secondary signals was computed by summing 
the detection rate by the size of the maf bin of the unimputed SNPs. 
The third set of simulations were performed to evaluate the difference in effect size 
estimates using the multisite linear regression method for parameter estimation from data 
representative of the LD structure in the CAGE dataset. For each of 500,000 iterations, 
four sites were chosen at random from a window extending from 200 kb upstream of the 
transcription start site to 200 kb downstream of the transcription termination site of a 
randomly picked gene in the CAGE cohort (excluding the BSGS data, since it includes 
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twins), and assigned an effect size from a uniform distribution of variance explained (VE) 
relative to environmental noise ranging between 0.02 and 0.1. The effect size β for an allele 
with maf p is computed as �VE/[2p(1 − p)] . Subsequently, each phenotype was 
simulated as βi* genoi + N(0,1), whereβi is the simulated allelic effect size for a SNP i, and 
genoi is the dosage of minor allele at the simulated SNP for a given sample. The 
significance threshold for sequential conditional detection of the variants in a sample of 
1839 CAGE individuals was set at P ≤10-5, since simulations indicated a ≤ 1% false 
discovery rate for null variants at this level. I evaluated (i) how many of the four SNPs 
were significant in sequential conditional modeling, (ii) the mean LD between each SNP 
and the other three SNPs in the model, (iii) the effect size estimates from the conditional 
and joint multisite models, (iv) the difference between these two estimates as a function of 
the mean LD, and (v) the rank of the discovered SNP for each peak eSNP and the modeled 
sites, which were assumed to be the causal variants for some trait. 
The fourth set of simulations was performed to evaluate the influence of two 
Bayesian methods for fine mapping that is sensitive to the LD structure at a locus. First, 
eCAVIAR was used to also assess the accuracy of co-localization of eQTL and GWAS 
signals. Summary statistics were generated for normally distributed traits where either one, 
two, or three sites chosen at random from contiguous intervals of 100 SNPs in the full 
sample of 1835 CAGE genotypes were assigned to explain between 2% and 10% of the 
variance. Effects were assigned in the same direction for each minor allele. Marginal single 
site estimates were generated by uni-variable regression, and then eCAVIAR was used to 
combine the Posterior Probabilities, which were multiplied together to yield the Co-
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Localized Posterior Probabilities (CLPP) with a significance threshold of 0.001 as 
recommended (Hormozdiari et al. 2016). Owing to the high computational burden, only 
4000 simulations were performed. GWAS variants are in general unlikely to explain this 
amount of variance, but the statistical evidence is approximately equivalent to that expected 
for typical trait associations where a SNP explains ≤ 0.1% of the variance in a sample of 
20,000 individuals. The effect of sample size was evaluated by fitting a single eQTL effect 
to just 200 individuals in each simulation. Second, the DAP simulations were performed 
using the adaptive algorithm, which estimates the number of causal variants from the data 
and also generates a list of possible sites that could explain the effect(s). Again, owing to 
the high computational burden, only 130 simulations were performed, using the same 
parameters as for the sequential conditional analyses with four assigned causal variants. A 
final set of simulations designed only to fine map three causal sites in a single moderate to 
high LD block extracted contiguous sets of 100 SNPs, and randomly assigned effects only 
on the condition that three sites selected from the set each had r2 ≥ 0.3 with one another. 
2.3 Results  
2.3.1 Underestimation of allelic effects by sequential conditional analysis  
 My basic simulation framework utilizes the current standard mapping approach of 
sequential conditional analysis, in which the residuals from discovery of each SNP are 
taken forward as the dependent variable in a new scan for an independent SNP (Yang et al. 
2012). To explore the performance of this strategy in the context of four causal regulatory 
variants in the vicinity of a typical gene, 500,000 simulations were carried out by randomly 
picking four SNPs within 200 kb up- or downstream of the TSS and TES ends of a 
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randomly chosen gene, from the imputed whole-genome genotypes of 1839 unrelated 
European ancestry individuals. I assigned each SNP an allelic effect size so as to explain 
between 2 and 10% of the variance of a trait otherwise uniformly distributed with a mean 
of 0 and SD of 1. Power to detect individual univariate effects of this magnitude is close to 
100% at the significance level P≤10-5. The sampling was performed across all genes so as 
to sample from the typical LD structure in the European ancestry human genome. 
Furthermore, effects were randomly assigned under three scenarios, with either four 
positive (4:0), three positive and one negative (3:1), or two positive and two negative (2:2) 
effects of the minor allele on the trait. For the eQTL detection, once the sequential 
conditional detection was completed, I determined which of the four causal variants was 
in high LD (r2 ≥ 0.8) with one of the discovered sites. If a peak was in high LD with more 
than one causal variant, it was assumed that it tagged the highest effect site. 
Table 2.1. Tagging Efficiency of Detection of Causal Variants with r2 cutoff 0.8 
            
        Number of                       Scenario (Positive: Negative effects)*  
Detected Causal Variants            4:0               3:1           2:2 
             
1                              0.6% (0.84)             1.4% (1.00)       1.2% (0.62) 
2                              5.7% (0.69)           10.4% (0.91)       12.8% (0.86) 
3                            28.2% (0.78)          24.3% (0.85)    22.5% (0.76) 
4              55.5% (0.89)      59.0% (0.92)   60.2% (0.90) 
             >4                            10.0% (0.63)           5.0% (0.66)     3.3% (0.56) 
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*  % indicates the percent of cases with the indicated number of independent discovered variants; numbers 
in brackets are the proportion of discovered variants that are in LD (r2 > 0.8) with one of the simulated causal 
variants. 
Table 2.1 summarizes the “tagging efficiency”, namely the percent of simulations 
in which the indicated number of significant independent sites was detected, as well as the 
proportion of the discovered variants that are in high LD (r2 ≥ 0.8) with one of the simulated 
causal variants. Across all three scenarios, at least three independent peaks are detected in 
90% of the simulations, and at least four independent peaks in two thirds of the simulations. 
Notably, in the scenarios where all four minor alleles influence expression in the same 
direction, 10% of the simulations detected five or more independent peaks, at least one of 
which must be a spurious association, despite a ≤ 1% false discovery rate for univariate 
associations of the same magnitude. The proportion of credible intervals (r2 ≥ 0.8 regions 
around each discovered variant) that contain the actually simulated site ranges between 
85% and 90% in each scenario, again indicating relatively poor localization of the causal 
variant.   
Table 2.2. Detected true causal variants in simulations with 4, 3 and 2 causal variants 
              
Detected                            4 SNP Scenario           3 SNP Scenario           2 SNP Scenario 
               variants                4:0     3:1        2:2    3:0        2:1                     2:0      1:1 
             
0   1.1%   1.2%   1.4%   2.1%   1.9%   5.5%   6.3% 
1   5.5%   6.0%   6.0% 12.1% 15.1%   9.4%   9.1% 
2 18.4% 22.3% 23.7% 17.6% 17.9% 85.1% 84.6% 
3 23.7% 23.4% 22.1% 68.2% 65.0% 
4 51.3% 47.1% 46.7%     
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Similar results are reported in Table 2.2 for the reciprocal measure of what fraction 
of simulated variants is captured by discovered variants. It includes results for simulations 
with just two or three causal variants, and reports the percentage of cases where the causal 
variant was within the r2 ≥ 0.8 credible interval for a discovered peak. Across the sets of 
500,000 simulations, at least two variants are detected > 85% of the time, but the power to 
detect all of the multiple eSNPs is a function of the number of sites operating in the same 
direction. It is highest for the case where the minor alleles for all four variants have effects 
in the same direction and least where two are in one direction and two in the opposite 
direction. In the 4:0 scenario, three or more of the four eSNPs are detected three-quarters 
of the time, whereas this proportion drops toward two-thirds with the simulations for 2:2. 
No variants are detected in just over 1% of the simulations, and just one variant in ~6% of 
them, while 80% of the variants are detected overall. This proportion rises to 90% for the 
two-variant simulations, illustrating how multisite interactions reduce the discovery of 





Another way to consider the power of multisite detection is to ask how much of the 
variance explained by the four SNPs is captured by the discovered variants. Box and 
whisker plots in Figure 2.2 shows that, under all three scenarios, on average 85%–90% of 
the variance is captured, namely in these simulations ~15%–20% of the transcript 
abundance. Although effect sizes of all SNPs were drawn from the same distribution, the 
first discovered SNP (rightmost box in each panel) typically explains between one-third 
Figure 2.2 Proportion of variance explained by detected eSNPs in simulations. Box 
and whiskers show median, interquartile range, and 95% C.I. for the proportion of 
variance explained under three scenarios for 500,000 simulations of four sites 
affecting gene expression. From left to right in each simulation, Simu is the variance 
explained by the known sites, Multi is the result fitting discovered eSNPs jointly, Uni 
is the result of summing the effects from sequential conditional modeling, and Single 
is the effect of the peak detected eSNP. The y-axis shows the proportion of variance 
explained. Scenarios are 4:0, all four minor alleles with effects in same direction; 3:1, 
one minor allele effect in the opposite direction; 2:2, two minor alleles on one direction 
and the other two in the opposite direction. eSNP, expression single nucleotide 
polymorphism. 
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and one-half of the expected variance, suggesting that it often tags some of the effect of 
another site. Since the primary SNP captures on average more than two thirds of the 
heritability at each locus in actual peripheral blood data (Lloyd-Jones et al. 2017), it is 
likely that secondary and tertiary SNP effects are, in reality, smaller than primary SNP 
effects. As expected, summation of the independent contributions from the sequential 
conditional models, or fitting all of the discovered variants simultaneously in a 
multivariable model, explains very similar proportions of the variance overall. Similar 
results are seen with two or three simulated causal variants. 
2.3.2  Estimation of the proportion of secondary associations that are false positives 
The detection of more association peaks than the number of simulated sites implies 
that some fraction of peaks are false positives that arise due to sampling artifacts in the 
presence of high LD, whereby an imperfectly tagged site is split into two or more spurious 
signals. An example is shown in Figure 2.3A and B, contrasting the local Manhattan 
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profiles for a single causal variant that splits into two associations when the peak SNP, 
rs9806753, is excluded from analysis.   
Figure 2.3 False multiple eQTL detection due to unimputed variants. (A, B) example 
showing multi-eQTL due to poor tagging. (A) SNP rs9806753 (European-ancestry 
maf = 0.23) was simulated to generated an eSNP effect, but removal of this variant 
and all SNPs within r2 > 0.5 in analysis, (B) results in the effect captured by a primary 
(rs62010876, maf = 0.10) and secondary (rs1974961, maf = 0.13) signals. (C) Empirical 
maf distribution of 1.4 M unimputed 1000G (red) and 8.3 M imputed 1000G variants 
in CAGE (blue), showing shift to lower frequencies for variants not tagged. (D) 
Tagging efficiency as a function of maf based in mean r2 for the strongest correlated 
SNP for 10,000 randomly selected variants in the CAGE. (E) Corresponding signal 
detection rate at P < 10-5 for randomly assigned effect sizes, explaining between 2% 
and 8% of a simulated gene expression trait for primary (red) and secondary (blue) 
signals when the simulated variant is excluded from the analysis. (F) Cumulative 
proportion of sites expected to generate a false multiple eQTL detection. 
Multiplication of this proportion by the number of unimputed SNPs in genic regions 
and the actual proportion of SNPs that have effects (unlikely to be >1%) yields up to 
400 possible false positive secondary associations. 
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To explore the frequency with which this occurs, I conducted simulations assuming a single 
causal variant based on the genotypes measured in 1839 European ancestry samples from 
the CAGE cohorts (see Methods). Randomly assigning causal effects resulted in the 
appearance of a secondary signal at P ≤ 10-5, conditioned on the causal site, at 0.3% of the 
loci. This is approximately as expected given 8.3 million imputed SNPs at 22,000 loci, and 
is also the same as the false discovery rate of primary signals in the absence of any 
simulated causal locus; that is to say, the random expectation is for 0.3% of transcripts to 
have a false eQTL discovery at P ≤ 10-5 in the CAGE dataset. However, this ignores the 
possibility that the causal variants are not present in the imputed genotypes. Of the 9.7 
million SNPs, indels, and CNV with maf ≥ 0.01 in the European populations in the 1000G 
database, 1.9 million are not imputed in the CAGE samples. Figure 2.3C shows that the 
maf distribution for these variants is strongly shifted toward rarer alleles relative to the 
imputed SNPs, and is centered at a maf ≥ 0.02. Consistent with Yang et al. (2015), the 
average tagging efficiency (r2 value) of these SNPs is a function of maf, being >0.7 for maf 
>0.05, but dropping to <0.5 for maf = 0.01, as seen in Figure 2.3D.   
Since I cannot simulate effects at nonimputed SNPs, I approximated such alleles 
by randomly simulating a causal variant from the CAGE SNPs with the same frequency 
distribution, but excluding it from the analysis along with all variants that would tag it at 
the typical level observed for the nonimputed SNPs of the same maf. I then asked how 
often the effect is captured by multisite signals, as a function of residual tagging efficiency. 
I allowed for increased effect sizes with lower maf by simulating effects in the constant 
range of 2%–10% of the variance explained. The proportion of such pseudo unimputed 
 47 
SNPs that generate primary signals is reduced with lower maf, due in part to the smaller 
proportion of variance explained by the less common variants that partially tag them. For 
common variants, there is almost always a second site in high enough LD to capture most 
of the causal signal in the absence of genotypes at the causal variant, but rare variants are 
insufficiently tagged to generate a signal at all, 90% of the time. In the presence of tagging 
SNPs with r2 ≥ 0.5 to the “unobserved” causal variant, false secondary associations are 
observed ~40% of the time. At the other end of the spectrum, rare variants (maf ≤ 0.01) 
that produce a primary signal at a tagging SNP with 0.1 ≤ r2 ≤ 0.3 also produce a secondary 
signal but less frequently. The blue curve in Figure 2.3E indicates the inferred fraction of 
unimputed variants that could induce secondary signals as a function of maf, and Figure 
2.3F shows that the cumulative proportion of such spurious eQTL weighted by observed 
maf proportions approaches 20%. Approximately 14% of the 1.9M unimputed variants are 
located within 200 kb of a gene, and assuming that 0.1% of these actually have an eQTL 
effect, this suggests the potential for ~250 such effects.   
These computations argue that up to 10% of the observed 2300 multisite 
associations reported by Lloyd-Jones et al. (2017) have the potential to be false signals 
driven by inefficient tagging of unimputed variants in CAGE. The proportion could be 
greater if the fraction of functional SNPs is higher, as suggested for example by Tewhey et 
al. (2016), who used a very sensitive MPR assay to implicate 3% of regulatory sites in 3642 
eQTL regions (842/32,373 tests) as capable of modulating transcript abundance. However, 
the proportion of sites with detectable signals capable of explaining > 2% of the variance 
is certainly lower, and 1 in 1000 (0.1%) is a reasonable estimate given that there are of the 
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order of 1300 documented variants in the vicinity of each gene and no more than 30% of 
expressed genes have a secondary eQTL signal.  
Synthetic associations due to even rarer variants may be expected to generate split 
associations as well (Dickson et al. 2010; Zhu et al. 2012). Yang et al. (2015) found that 
~20% of the variance for height can be explained by SNPs with maf ≤ 0.1, in part due to 
larger effect sizes of prevalent very rare SNPs, many of which are likely secondary 
associations. We also found that there is an excess of rare variants (maf ≤ 0.01) influencing 
extremes of gene expression, also with a slightly larger distribution of effect sizes than 
common variants (Zhao et al. 2016). Too many unknown parameters need to be evaluated 
to give a good estimate of the number of false positive secondary associations due to 
synthetic effects of very rare alleles, but it may be another few percent. 
Figure 2.4.  The single causal variant assumption biases fine mapping of causal 
variant locations. Each curve represents the cumulative probability distribution for 
RTC scores for the primary causal variants under a model with a single causal 
variant (purple), or with four causal variants under scenarios 4:0, 3:1, and 2:2 (blue, 
green, red curves, respectively). RTC scores close to one imply equivalence of the 
significance values of the eQTL and causal variant. eQTL, expression quantitative 
trait locus; RTC, Regulatory Trait Concordance. 
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2.3.3 Effect of multisite modeling on accuracy of localization of associations 
A possibly more important measure of estimation bias is the location of the peak 
SNP relative to the causal site. The most straightforward measure of co-localization is the 
Regulatory Trait Concordance (RTC) score (Nica et al. 2010), which is intuitive and easily 
implemented on the scale of the simulations. It is essentially a ranking of the significance 
of the detected eQTL P-value relative to the casual site, RTC = (NSNPs - Rankcausal 
SNP)/NSNPs, where a value of one indicates identity, and zero that the two sites are in the 
same locus but highly unlikely to be capturing the same signal. Figure 4 plots the 
cumulative frequency distribution for RTC scores for the primary eQTL signals relative to 
the largest effect causal variant in each simulation, contrasting the 4:0, 3:1, and 2:2 
scenarios. For comparison, under a single variant model, RTC is always close to one as 
expected [note that, since we do not simulate the GWAS signal as well, these values are 
inflated relative to data where the identity of the actual causal variant is unknown (Nica et 
al. 2010). For 10% of simulations in the presence of multiple regulatory variants, the RTC 
score of the primary SNP drops below 0.9, again with greater tendency toward mis-
estimation of the eQTL location in models with opposing effect directions of the minor 
alleles. This analysis confirms the results in Table 2.2, indicating that up to 15% of all 
detected SNPs are not in high LD (r2 > 0.8) with a simulated variant in the imputed panel 
of SNPs.  
Localization of tertiary and quaternary signals is affected more strongly, but 
intriguingly, considering just associations within r2 > 0.8 of a simulated SNP, the secondary 
signal is slightly more likely to be the first or second ranked SNP for one of the causal 
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variants than is the primary signal. This is true under all three scenarios, which have very 
similar profiles to that shown for the 3:1 scenario in Figure 2.5 (since there is wide variance 
in the number of SNPs in each region, we simplified the analysis by reporting just the SNP 
ranks in this figure, rather than RTC). It should be noted that there is not strong 
concordance between the relative proportion of variance explained by the causal variants 
and whether they are the primary through quaternary association, since LD has a strong 
influence on detection power. Although the vast majority of discovered sites are within 
three or four SNPs of at least one of the four causal variants when they are in high LD with 
one of them, it cannot be concluded that the order of discovery corresponds to the true 
order of effect sizes. 
2.3.4 Joint fitting pairs of known causal variants accurately estimates effect sizes 
Before addressing the accuracy of effect size estimation following stepwise 
conditional analysis, it is worth noting that in the case where the identities of two causal 
Figure 2.5. Signal ranks of simulated causal variants. The number of simulations in 
which a discovered variant was the indicated rank (left to right) for the first through 
fourth discovered variant (front to back). Rank refers to the number of SNPs with a 
smaller p-value than the modeled causal variant, where 1 implies the causal and 
discovered are the same SNP, 2 that one other SNP in the LD region had a smaller p-
value, and so forth. Only cases where the discovered variant was within r2 >0.8 of the 
causal variant are shown. 
 51 
variants are known a priori, joint fitting of the two SNPs in a single regression on transcript 
abundance always results in more accurate effect size estimates given a large sample size.  
The bias in estimation due to linkage disequilibrium between pairs of SNPs is a function 
of the two effect sizes (β1 and β2), the correlation between the SNPs (r), and the ratio of the 
square root of the product of their allele frequencies (Yang et al. 2012):  
                       Ê(β1) - β1 = rβ2 �𝑝𝑝1(1 − 𝑝𝑝1)/[𝑝𝑝2(1 − 𝑝𝑝2)]           
This is maximized for pairs of SNPs at the same frequency, increases with high LD, 
and can be either positive or negative depending on whether the signs of the minor allele 
effects are coupled or not.  Figure 2.6 provides a visual summary of the biases, compared 
with the effect of jointly fitting the two SNPs with a sample size of 2,000, which uniformly 
improves the effect size estimates.   
Three results deserve highlighting. First, for each combination of allele frequencies, 
increasing the allelic effect size results in more severe biases, in the most severe cases over- 
or under-estimating the effects by as much as 50% of the variance explained. Second, the 
first picked SNP (with the larger effect size) has the greater deviation between the estimated 
and true effect size.  This makes intuitive sense as the larger effect will generally be the 
first detected one and absorbs much of the effect of the other SNP, which will typically be 
under-estimated in the conditional analysis, but to a lesser extent.  If the deviation is 
computed simply on the uni-site unconditional values, the opposite result is obtained: the 
deviation is greatest for the smaller effect site.  Third, the mis estimation is greatest for 
lower allele frequencies, which is particularly noteworthy since most eQTL have maf in 
the range of 0.1 to 0.3.  
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Figure 2.6. Simulation of the influence of minor allele frequency and β on allelic effect 
size estimation. Left side, sequential conditional modeling; right side joint multi-site 
modeling, with n= 2,000.  Top row LD r2 = 0.5, Middle row, LD r2 = 0.1, Bottom row 
LD r2 = 0.9. The 25 sectors on each panel show results for combinations of two alleles 
with maf from 0.1 to 0.5 (left to right, top to bottom), within which each circle 
represents the average of 100 replicate simulations for allelic effects explaining from 
2% to 30% of the expression variance (left to right, bottom to top). Circle size and 
color is proportional to the absolute value of the deviation between the estimated and 
actual effect size β in standard deviation units. Transition from white to red 
represents greater deviation for allele 1; larger circles represent greater deviation 
from the simulated β for allele 2.  Empty fields arise because the indicated level of LD 




I also considered the power to detect joint effects in the presence of LD.  As the p 
value cutoff for detection becomes more stringent, the bias in estimation becomes more 
severe, since the first picked SNP absorbs the effect of both alleles into the same estimate, 
leaving the statistical power of the other allele, conditioned upon the first one, close to zero.  
With a sample size of 2,000 and intermediate LD, when both alleles are modeled jointly, 
power to detect both effects remains high across the plausible parameter space once the 
effect size exceeds 5% variance explained, and the estimation for the beta value is still 
accurate. Down-sampling suggests that in order to estimate effects within 0.1 standard 
deviation units, for pairs of variants with LD r2 ~ 0.9, each explaining 10% of the variance 
(namely having effect sizes of at least a half a standard deviation unit), a sample size of at 
least 900 is required.  
Consequently, most small sample eQTL studies will fail to resolve linked sites into 
two effects.  These results indicate how the typical assumption that an eQTL effect is due 
to a single variant in a set of credible SNPs in high LD is potentially highly biased.  Similar 
conclusions apply to the situation where two SNPs operate in opposite directions, with the 
additional dilemma that they will not be detected at all and consequently strongly under-
estimate the regulatory variance at a locus. 
2.3.5 Mis-estimation of allelic effects sizes by sequential conditional analysis 
Even though the sequential conditional and multisite models capture essentially 
equivalent proportions of the variance tallied across sites, biases in estimation of individual 
site effects ought to be reduced by the multisite modeling. To quantify this difference, I 
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computed the deviation between the observed and true simulated effect sizes (β in sdu) for 
each discovered peak located within r2 >0.8 of an independent causal variant, and evaluated 
the absolute value of these deviations as a function of the mean LD between the causal 
variant SNP and the other three causal variants in the model. Figure 2.7A plots the 
difference between the models in Figure 2.7C and D, which show the average absolute 
value of the deviation for SNPs with the indicated true effect size and LD, for the sequential 
conditional estimates, and for multivariable models fitting all discovered variants jointly, 
respectively. The figure shows results for the 4:0 scenario where all minor alleles operate 
in the same direction. The scale from dark blue to yellow indicates mis-estimation of effect 
sizes ranging from less than 0.5 sdu to more than three units, where each pixel is averaged 
over the number of simulations with the indicated allele effect sizes and average LD in 
Figure 2.7B. 
Several results are noteworthy. First, for causal variants in low LD, as expected, 
neither model results in appreciable estimate bias, but once the average LD rises above 0.5, 
effects can be misestimated by more than the effect size. For example, for β = 0.5, the 
absolute value of the difference between the observed and true effect is typically between 
1 and 2 sdu, which depending on the allele frequency may correspond to at least 2% of the 
total gene expression variance. Second, for large effect alleles, the mis-estimation is 
appreciable even at intermediate levels of LD, and it is not unusual for estimates to be off 
by as much as 4 sdu under either model. 
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Third, overall, the multisite modeling corrects some of the sequential conditional 
analysis bias. The difference in performance of the two estimation procedures shown in 
Figure 2.7A, where most values are pale green, indicates close similarity of the estimates, 
but bluish-tinged bands imply that the multisite model gives a better approximation to the 
true effect size for LD centered 0.1, 0.4, and 0.8. Mis-estimation without multivariate 
estimation can be twice as severe for very large effect alleles, although these only account 
for a very small fraction of all simulated alleles. 
Figure 2.7. Biases in effect size estimation from conditional and joint analysis. All 
panels refer to 500,000 simulated data points where effect sizes were sampled from a 
uniform distribution to explain from 2% to 10% of the expression at a locus for each 
of 4 SNPs picked at random from 400kb intervals of the CAGE genotype data. Panel 
(A) compares estimates from joint and conditional modeling, as a heatmap of the 
average difference in panels C and D, where yellow indicates that joint modeling 
produces a larger estimated effect size, and blue a lower estimate with three bands of 
negative values indicating greater bias in the conditional estimates. Panel B shows the 
density distribution on the log2 scale of the number of simulations with alleles for each 
pixel with the indicated b (in standard deviation units, sdu) on the x-axis, and average 
LD with the other 3 sites at the locus on the y-axis. Panels C and D show the average 
absolute value of the deviation between the observed and known effect size for sites 
under the multi-site model where all discovered sites are fit jointly (C) or from single 
site estimates after each step of sequential conditional analysis (D), for the 4:0 scenario 
where all minor alleles have effects in the same direction.  
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Similar trends are seen for the 3:1 scenario, where one of the minor alleles operated 
in the opposite direction to the other three, as well as in the 2:2 scenario (Figure 2.6), and 
simulations with just two or three causal variants yield similar conclusions (Figure 2.9 and 
2.10 respectively). The advantage of joint modeling is reduced in the presence of opposing 
allelic effects, but still prevalent in the region with high allelic effect size and low LD; and, 
as noted above, a large proportion of causal sites are not discovered in the 2:2 scenario, so 
are not included in the estimation. 
 
Figure 2.8. Effect size estimation bias under the three scenarios with 4 causal variants. 
Each scenario includes 90,000 simulations and panels from left to right in each row 
show the average absolute value of the difference between the estimated multisite β 
and true β, the absolute value of the difference between the estimated sequential 
conditional β and true β, and the average difference between these values. Top row is 
results for four sites where the minor alleles have the same sign of effect, bottom row 
for two sites each with the same sign, middle row a mixture of three in one direction 
and one in the other. 
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In summary, stepwise conditional eQTL discovery is expected to discover between 
70% and 80% of eQTL within realistic effect size ranges typical of those reported in the 
literature. Once discovered, multi-locus estimation of effect sizes provides slightly more 
Figure 2.9. Effect size estimation bias under the two scenarios with 2 causal variants. 
Each scenario includes 90,000 simulations and panels from left to right in each row 
show the average absolute value of the difference between the estimated multisite β 
and true β, the absolute value of the difference between the estimated sequential 
conditional β and true β, and the average difference between these values. Top row 
is results for two sites where the minor alleles have the same sign of effect, bottom 
row for two sites with the same sign. 
Figure 2.10. Effect size estimation bias under the two scenarios with 3 causal variants. 
Each scenario includes 90,000 simulations and panels from left to right in each row 
show the average absolute value of the difference between the estimated multisite β 
and true β, the absolute value of the difference between the estimated sequential 
conditional β and true β, and the average difference between these values. Top row is 
for three sites, all with the same sign, and bottom row is one site operating in the 
opposite direction to the other two. 
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accurate estimates than the estimates from sequential conditional models, but for large 
effect alleles in high LD the corrections can be substantial. 
2.3.6 Bayesian modeling only slightly improves mapping of multisite associations 
Recently, a number of Bayesian approaches have been introduced that are designed 
to improve fine-mapping of eQTL effects (Giambartolomei et al. 2014, Zhou et al. 2013). 
One of these is eCAVIAR (Hormozdiari et al. 2016), which reports a Colocalization 
Posterior Probability (CLPP) based on the combined likelihood that a variant influences 
both the abundance of a transcript and a phenotype given the LD structure at a locus. The 
authors proposed a CLPP cutoff of 0.001 (for example, a posterior probability of 0.1 for 
the eQTL and 0.01 for a disease association), which corresponds in the simulations (Table 
2.3) to discovery of 80.7% of single variants sampled at random from contiguous blocks 
of 100% SNPs in the CAGE European ancestry cohort genotype data. The computational 
burden of evaluating all possible four site combinations is too large for this model to be 
applied in genome-wide scans. Instead, I performed 4000 simulations of 1835 individuals 
in the presence of two or three regulatory variants, as well as a normally distributed 
phenotype, and evaluated the CLPP distributions. In the case of two causal variants, just 
94.7% generated CLPP > 0.001, and for three causal variants, 84.9%. Figure 2.11 shows 
the cumulative distribution functions of the CLPP scores as a function of the number of 
causal variants, clearly documenting the trend for reduced confidence in joint localization 
as the degree of multisite regulation increases. Similar trends were seen with a more 
conservative CLPP cutoff of 0.01, confirming that interference among tightly linked sites 
reduces the power to detect independent causal variants. The upper red curve also indicates 
that the power to detect co-localization is greatly reduced with sample sizes of just 200 for 
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the eQTL sampling: in fact, just 60% of simulations with a single causal site yielded a 
CLPP > 0.001.  
Since eCAVIAR is not designed to cover intervals encompassing all of the 
regulatory regions of a typical gene and hence is not directly comparable with the stepwise 
conditional regression, I also evaluated the DAP algorithm (Wen et al. 2016). DAP is 
designed to identify independent credible intervals and report candidate SNPs across a 
locus, incorporating priors that weight likely functional or evolutionary evidence. Using 
the adaptive DAP procedure, which does not make any prior assumptions about the number 
of causal variants at a locus, I performed 130 simulations of four variants with effect sizes 
drawn as before to explain between 2 and 10% of the variance, all operating in the same 
Figure 2.11.  Co-localization with eCAVIAR in the presence of multiple regulatory 
sites. Cumulative Distribution Functions summarize CLPP scores for 4000 
simulations each with one, two, or three assigned causal sites within a contiguous 
block of 100 SNPs. Green, purple, and teal curves show progressive degradation of 
evidence as the number of modeled causal variants increases, for simulations with 
1835 subjects. The red curve shows that more than half of the simulations with just 
200 subjects for the eQTL component have CLPP < 0.01, and just one-quarter >0.1, 
compared with one quarter >0.98 with 1835 subjects. CLPP, Combined Likelihood 
Posterior Probabilities; eQTL, expression quantitative trait locus; SNP, single 
nucleotide polymorphism. 
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direction. The average number of detected variants was 3.76, which included 3.52 of the 
four simulated sites (88%) in the candidate list. Due to different statistical thresholds, it is 
difficult to compare this result with the stepwise conditional model, but it appears to be an 
improvement on the 80% reported in Table 2.2. As expected, DAP fails to detect true causal 
variants in the presence of high LD. 
Figure 2.12A shows the dependency of the number of discovered variants on the 
mean LD between the four simulated sites in each simulation, while Figure 2.12B shows 
how many of the true causal variants are detected. Notably, if all four variants are in a 
Figure 2.12. Fine mapping with DAP in the presence of multiple regulatory sites. (A–
C) Results for simulations with four causal sites drawn at random from 200 kb 
upstream and downstream of each gene. (D–E) Results for simulations with three 
causal sites drawn from 100 continuous SNPs, each in LD with r2 > 0.3. (A and D) 
show the estimated number of sites as a function of the mean LD between the sites, 
showing that as LD increases, detection of independent intervals decreases. (B and E) 
show the number of modeled (true) causal sites in the candidate lists, as a function of 
mean LD, which in this case increases for high LD. (C and F) show that the number 
of candidate sites increases with high LD, sometimes with 20 or more candidates 
defining a credible set for each true site. DAP, Deterministic Approximation of 
Posteriors; LD, linkage disequilibrium. 
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single block of high LD, no sites are detected since the posterior probabilities are dispersed 
across all of the variants. Across the full extent of up to 500 kb at most loci there are usually 
multiple LD blocks, so DAP, like stepwise conditional modeling, is quite efficient at 
detecting independent credible intervals. However, it consistently over reports the number 
of candidate variants and Figure 2.12C shows that this number also increases with LD. To 
confirm that DAP is still able to resolve multiple causal variants in the presence of high 
LD, I also ran 400 simulations with the constraint that three sites must be within r2 > 0.3, 
using the DAP-k algorithm with k = 3 (assuming three sites), showing the results in Figure 
2.12D–F. In this case, the number of detected independent associations dropped to 1.95, 
namely 65% of the simulated number. Although 79% of the simulated variants were among 
the candidate lists, these can become very large with a ratio of ten-to-one candidates for 
each true causal variant. Stepwise conditional analyses on the same simulations with a 
cutoff of P ≤ 10-5 discovered on average 1.5 (52%) of the three simulated effects and 
included 2.29 (76%) of the sites within the credible interval. Consequently, DAP does 
appear to improve performance, at the cost of a considerably higher computational burden.  
 
2.4 Discussion 
Studies of the genetic regulation of gene expression are making a meaningful 
contribution to the interpretation of GWAS results, as they provide functional insight into 
the nature of the causal genes.  Efforts to fine map causal variants are, however, 
complicated by the limits of statistical resolution as it is not uncommon for tens, if not 
hundreds, of polymorphisms in a credible set to have similar statistical support (Gaulton et 
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al. 2015; Kichaev and Pasaniuc 2015).  Inclusion of experimental evidence from epigenetic 
marks or signatures of evolutionary conservation into scores such as CADD ((Kircher et 
al. 2014) and CATO (Maurano et al. 2015) may improve resolution, along with methods 
such as RTC (Nica et al. 2010) and PICS (Farh et al. 2015) which prioritize variants based 
on the structure of linkage disequilibrium at a locus.  In general these approaches assume 
parsimony, namely that there is a single variant that is responsible for the major GWAS or 
eQTL signature. Although it has become increasingly clear that many loci harbor multiple 
independent regulatory variants, I argued above that if the parsimony assumption is relaxed 
and it is assumed that multiple sites in strong linkage disequilibrium commonly account 
for a signature that is compounded into a single significant association, then the estimates 
from sequential conditional analysis can be highly biased.   
To summarize, I find that over 5% of primary sites and more than a quarter of all 
causal sites are unlikely to be tagged at all; that in the presence of multi-site regulation at 
least 15% of all mapped sites are not in strong LD with any of the multiple imputed causal 
variants at a locus; and that another 10% of the associations are plausibly due to splitting 
of the signal due to an unimputed site.  Taken together with the confirmation that over a 
third of all eGenes have two or more independent eSNPS, these results suggest that at least 
5% and perhaps as many as a quarter of mapped credible intervals may not include the 
actual causal variant.  
When choosing methods to perform multiple eQTL detection, I first used a 
conditional analysis method. Although multiple methods, like FMQTL, DAP, CAVIAR, 
PAINTOR, FINEMAP (Wen et al., 2015; Wen et al., 2017; Hormozdiari et al., 2014; 
Kichaev et al. 2014; Benner et al., 2016) have been developed to detect multiple QTLs, 
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most of these methods have been used to explored the confidence intervals for the causal 
variants, but  there has not been any estimation of effect size parameters, such as β. 
CAVIAR, which is based on summary statistical association results, uses a greedy method 
to find a subset SNPs with a specific confidence (95% by default) that causal variants are 
included. PAINTOR uses a similar algorithm. CAVIAR enumerates all possible causal 
status, and to reduce the computational burden, a maximum number of causal variants must 
be chosen (default is 2, according to the newest version). FMQTL applies the MCMC 
method to explore the causal status space, and uses a posterior inclusion probability to 
choose the confidential interval containing possible causal variants.  To reduce the 
computational burden, DAP was developed to explore high probability causal sites. 
FINEMAP uses similar a logical framework as CAVIAR, but uses a Shotgun Stochastic 
Search method to only explore the causal status with high probability.   
Theory and simulation both indicate that if two linked sites both influence a trait, 
including gene expression, then multi-site models will uniformly outperform sequential 
uni-site ones with regard to estimation of the true effect size.  When the identities of the 
variants are known, sample sizes of several thousand individuals are sufficient to jointly 
estimate their effects with high accuracy even in the presence of high levels of linkage 
disequilibrium with r2 up to or even exceeding 0.9.  The problem is that the identities of 
the variants are generally not known, and there are no established methods for 
comprehensive screening transcriptome-wide for localization of multi-locus local eQTL 
effects.  The two exhaustive search algorithms, PAINTOR (Kichaev et al. 2014) and 
CAVIARBF (Chen et al. 2015) hold promise for detailed dissection of multi-site models 
at individual loci, along with the Bayesian shotgun stochastic search algorithm, FINEMAP 
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(Benner et al. 2016).  This and the deterministic approximation of posteriors (DAP) 
approach to iterative refinement of multi-SNP models (Wen et al. 2016) should be 
evaluated for their ability to identify and estimate more of the multi-site effects than those 
obtained with the sequential conditional approach.  I also caution that it is likely that single 
site effects may sometimes be artificially split into two or more linked contributions under 
each of these strategies.  Consequently, for this study I adopted the existing standard 
approach of sequential conditional analysis. 
I then estimated the bias in the estimates from the conditional analysis, by fitting 
multi-locus linear models to all of the discovered eSNPs at each locus.  This revealed only 
modest improvements in accuracy for most of the discovered sites, but the modesty is in 
part an artefact of the discovery bias introduced by the sequential conditional process.  The 
simulations assuming 2 to 4 effective sites per locus across a wide and representative range 
of linkage disequilibrium, show that in a sample size of 2,000, in general no more than 
85% of the simulated causal sites are tagged by discovered associations that explain 
typically observed magnitudes of effect and would almost always be detected if a single 
site explained the variance.  Similarly, Lloyd Jones et al. (2016) estimated that in the CAGE 
dataset, on average between 50% and 75% of the heritability due to locally acting 
regulatory polymorphism can be attributed to discovered variants.  Multi-site modeling re-
adjusts the remaining estimates typically by between 0.1 and 0.5 standard deviation units, 
which depending on the allele frequency accounts for between 2% and 5% of the variance 
explained, and only rarely more than 10%.    
However, any variants with effect sizes greater than 1 sdu, and whose average r2 
with the other 3 SNPs is greater than 0.9, will be mis-estimated in both the single site and 
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joint models, typically by 1.5 sdu or more.  The mis-estimation is on average the greatest 
where all of the effects are in the same direction, but is consistently observed also in the 
presence of associations with alternate signs. Since the number of loci with 2, 3, 4 and so 
forth discovered variants approximately halves for each additional variant, it seems 
reasonable to infer that at least 10% of loci actually have four or more eSNPs (two or three 
of which are discovered), and that perhaps one quarter have three or more eSNPs (of which 
one or two are discovered).  I conclude that the sequential conditional estimates of eQTL 
effects are actually highly biased for a considerable proportion of variants.   
Although this does not impact the total amount of variance explained by the 
discovered variants, it is likely to greatly impact fine mapping efforts, particularly where 
two or more effects are collapsed into one site in a credible interval. Thus, while large 
datasets have very good power for detection of complex regulatory contributions for 
individual genes, there are a host of technical and statistical reasons why fine mapping of 
causal variants remains a challenge.  There are two immediate strong implications of these 
results.  One is that even though the majority of identified eSNPs are expected to map to 
credible intervals that include the causal variant (Gusev et al. 2014; Finucane et al. 2015), 
there will also be many instances where incongruence between the statistical interval and 
chromatin or other functional evidence (Huang et al. 2015) is to be expected.  The causal 
variant may simply be poorly mapped due to interference among linked functional sites.   
This effect may also influence the fine mapping of pleiotropic associations (Fortune et al. 
2015).  
The second implication of the high frequency of multi-site regulation is to 
emphasize caution in using univariate statistical support for an eSNP effect as sufficient 
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evidence that an association between a SNP and a trait is evidence for causation.  At a 
minimum it is imperative that the full spectrum of eSNP effects across the locus be 
evaluated to confirm that the site is not simply in LD with higher likelihood eSNPs that are 
not themselves associated with the trait. Experimental validation of individual sites seems 





PolyQTL: Bayesian multiple eQTL detection with control for population structure 
and sample relatedness 
ABSTRACT: Expression quantitative loci (eQTL) are being used widely to annotate and 
interpret GWAS hits. Recent studies have demonstrated that individual gene expression is 
often regulated by multiple independent cis-acting eQTL. Diverse methods, frequentist and 
Bayesian, have already been developed to simultaneously detect and fine-map such 
multiple eQTL, but most of these ignore sample relatedness and potential population 
structure.  This can result in false positives and disrupt the accuracy of fine-mapping. Here 
I introduce PolyQTL software for identifying and estimating eQTL effects.  The package 
incorporates a genetic relatedness matrix to remove the influence of population structure 
and sample relatedness, while utilizing a Bayesian multiple eQTL detection pipeline to 
identify the most plausible candidate causal variants at one or more independent loci 
influencing abundance of a transcript. Most of contents in this chapter have published in 
Bioinformatics, as Zeng and Gibson, 2018 “PolyQTL: Bayesian multiple eQTL detection 
with control for population structure and sample relatedness”. 
3.1 Background 
The idea of performing eQTL detection by genome-wide association combining genomic 
biomarkers and gene expression measurement was first reported in 2005 (Cheung et al., 
2005). Stimulated by the great success of genome-wide association studies (GWAS) 
(Visscher et al., 2017; Albert and Kruglyakk, 2015), more than 100 genome-wide eQTL 
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studies have been performed on a variety of human tissues. Despite its great success in 
identifying regulatory effects, and widespread application in interpretation of GWAS 
results, new evidence reveals that only a limited proportion of GWAS hits seem to fine 
map to credible eQTL intervals. Part of the reason is that most eQTL studies are performed 
with a limited number of samples, usually fewer than 1,000, resulting in constrained 
statistical power. Owing to this low statistical power, only a limited number of genes will 
have significant signals, the winner’s curse will lead to over-estimations of effect sizes, 
and non-causal variants will often have the strongest signal. To overcome these limitations, 
some studies, such as the eQTLGen consortium, have collected study samples from many 
labs around the world, and performed meta-analysis to discover cis- and trans-eQTL 
signals. In this type of analysis, a common procedure is to conduct principal component 
analysis on the genotypes and extract several PCs (usually 4), which are treated as 
covariates when conducting the association study. However, control for population 
structure with PCA may not be sufficient to rule out the influence of potential population 
structure or cryptic relatedness, especially when samples are collected from diverse 
ancestries. A more powerful strategy is to perform mixed linear modeling. 
An implicit assumption of eQTL studies is that each region parsimoniously 
contains a single eQTL, and most of the available packages have been developed with this 
in mind. However, most genes are regulated by numerous regulatory elements, including 
promoter, enhancer and suppressor elements. These can be located several hundred kilo-
bases from the transcription start site, yet still contain polymorphisms that contribute to the 
variance in gene expression.  
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A common approach to finding multiple causal variants is to first calculate marginal 
association statistics for each variant, and then perform stepwise conditional analysis 
including lead associations as covariates in each successive model (Yang et al., 2014).  
Investigators can then focus on the top ranked independent variants for follow-up studies. 
Bayesian method have also been shown to be powerful for performing association analysis 
and fine-mapping, and multiple packages are available, including CAVIAR (Hormozdiari 
et al., 2014), CAVIARBF (Chen et al., 2015), FINEMAP (Benner et al., 2016), FMQTL 
(Wen et al., 2015), and DAP (Wen et al., 2016). However, a major caveat that precludes 
their use on many datasets is that they use only summary statistics (CAVIAR, CAVIARBF, 
FINEMAP), ignoring any population structure and relatedness, or require external ancestry 
information to control for population structure in meta-analysis.  
Here I present PolyQTL, a statistical approach to association analysis and fine 
mapping that addresses the limitations of these existing methods. The novelty of PolyQTL 
lies in that it provides a full powerful Bayesian framework for fine mapping of causal 
variants that can also be used with cohorts that include samples from related individuals.  
3.2 Method 
3.2.1 Remove influence of polygenic background 
Suppose that the expression of a given gene is under partial control of a polygenetic 
background, expressed as y=Xβ+ε, where y is a vector of transcript abundance phenotypes 
with length n, X is a genotype matrix, βis a vector of random genetic effects distributed 
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normally N(0, 𝑉𝑉𝑔𝑔2/M), M is the number of causal variants, and ε is a random factor with a 
normal distribution N(0, 𝑉𝑉𝑒𝑒2). Covariance between two samples can be described as (1/m 
∑ 𝑋𝑋𝑖𝑖𝑖𝑖 ∗ 𝑋𝑋𝑗𝑗𝑖𝑖𝑚𝑚𝑖𝑖=1 )*  𝑉𝑉𝑔𝑔2  +  𝑉𝑉𝑒𝑒2𝐼𝐼, where i and j index individuals, m is the number of total 
variants, and I is the identity matrix. When there is no population structure or relatedness 
present, the covariance will be almost identical to ( 𝑉𝑉𝑔𝑔2  + 𝑉𝑉𝑒𝑒2 ) 𝐼𝐼 ,  and a standard 
regressionmethod can be applied safely (Joo et al., 2016). However, when there is 
population structure or relatedness among individuals, the non-diagonal elements in the 
covariance matrix largely depart from zero, and estimation will be biased.  Figure 3.1A 
illustrates these properties as an n x n matrix of genetic covariance where the bottom left 
to top right diagonal represents siblings, and the bottom left and top right quadrants imply 
increased similarity among individuals in two sub-populations. 
Figure 3.1 Pipeline of PolyQTL. A illustrates the complexity of simulation of related 
individuals and population structure. Green shading represents the correlation 
between pairs of samples, with twins represented by the top-left to bottom right 
diagonal in the bottom left quadrant, and population structure represented by the 
closer similarity of individuals within the bottom left and top right quadrants.  B 
shows transformation of the phenotype and genotype with the square root of the 
covariance, and (C) a Bayesian method is used to compute a posterior inclusion 
probability (PIP) for each variant, ranking candidate variants. 
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In PolyQTL, I first estimate the covariance parameters 𝑉𝑉𝑔𝑔2 and 𝑉𝑉𝑒𝑒2 with Restricted 
Maximum Likelihood (REML), and to remove the influence of population structure, I then 
transform the phenotype and genotype by dividing by the square root of the phenotype 
covariance, which results in independent multivariate normal distributions (Figure 3.1B) 
(Abney et al., 2002). After this transformation, a Bayesian method extending previous 
methods is used to compute a posterior inclusion probability (PIP) for each variant, leading 
to a ranking of candidate causal variants (Figure 3.1C). PolyQTL can be used to estimate 
multiple regulatory variant effects simultaneously, which is computationally burdensome, 
or run in conditional mode estimating effects at each independent eQTL separately. 
3.2.2 Conditional analysis 
In eQTL analysis, a cis-region may be defined as 100kb, 200kb or even 1Mb around 
the transcription start site (TSS), usually containing hundreds or thousands variants to 
explore. Evaluation of all possible variants in such an interval is constrained by 
computational burden. To overcome this limitation, and assuming that causal variants are 
sparsely distributed, I provide the option of conditional analysis, in which newly detected 
signals are included in the regression model, allowing detection of independent signals at 
each locus. In each step, the covariance matrix is re-estimated, and used to control for the 
population structure and relatedness, by implementing the mixed linear regression 
component of GEMMA (Zhou and Stephens, 2012). 
3.2.3 Parallelization 
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I utilized the C++ OpenMP library to compute causal state posterior probabilities, 
running the computations in parallel on the Georgia Tech Biocluster when multiple CPUs 
are available.  
3.3 Simulation 
3.3.1 Population structure 
Two subpopulations were simulated, with ancestral allele frequencies x for causal 
variants uniformly distributed on [0.1,0.9], and subpopulation allele frequencies were 
sampled from a beta distribution with parameters x(1– Fst)/Fst and (1–x)(1– Fst)/Fst, where 
Fst is the population differentiation index (Yang et al., 2014). To mimic the LD structure 
in real data, 100 variants in the 400kb cis-regions of randomly chosen genes in the 1,843 
1000G non-African individuals (Auton et al., 2015) were used to simulate single eQTL 
explaining 5% of the phenotype variance. A parameter representing the maximum number 
of causal variants was set to be 1 both in DAP and my method for each tested interval. 
To evaluate the performance in the scenario of multiple causal variants at a locus, 
I also conducted similar simulations, except that two causal variants were simulated, with 
effect sizes ranging from 4%~8%. The parameter of the maximum number of causal 
variants in this case was set to be 2. 
3.3.2 Genetic relatedness 
A complex family structure may exist in real data. In this simulation, I adopted a 
simplified family structure design in which I set 400 individuals to be identical twins in 
one of the two sub-populations.  These individuals have identical genotypes, and hence 
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relatedness equal to 1.  Since real-world datasets often include family members with lesser 
degrees of relatedness, I also simulated situations where 20% of the individuals were set 
as sibling pairs, namely with 50% allele sharing across the 5,000 simulated causal variants.   
3.3.3 Large-effect eQTL and polygenic background 
To mimic the LD structure in real data, 100 variants in the 400kb cis-regions of 
randomly chosen genes in the 1,843 1000G non-African individuals (Auton et al., 2015) 
were used to simulate two eQTL, each explaining 4%~8% of the phenotype variance, 
respectively.  600 simulations were performed in each parameter setting, each involving a 
different randomly selected gene.  Some simulations result in both causal variants lying in 
the same LD block, others separate them into smaller blocks between which r2 < 0.3.  In 
the modeling step, the parameter representing the maximum number of causal variants 
assumed per interval was set to be 2 both in DAP and PolyQTL. 
To evaluate the performance in the scenario of single causal variants, I conducted 
simulations in which a single causal variants was simulated, with effect size 5%. The 
parameter of the maximum number of causal variants was set to be 1. 
For simulation of the polygenic background, 5,000 variants were chosen to be 
causal, and the genetic relationship matrix (GRM) was estimated from the genotypes of 
4,500 of these causal variants. The genetic contribution was calculated with the GRM and 
the simulated heritability. 
3.3.4 Control of the False Positive Rate 
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To evaluate how well PolyQTL controls the type 1 error (false positive rate), I 
performed simulations as before, except that causal variants were modeled as having a null 
contribution.  Population structure (Fst =0.05, and 0.1) was simulated as in previous 
simulations in PolyQTL, and the results were compared with DAP (which ignores it in the 
computations). I used a conserved criterion, the Bayesian False Discovery Rate, as 
described in Wen, 2016.  This is calculated as 1- ∑ 𝑃𝑃𝐼𝐼𝑃𝑃𝑖𝑖𝑛𝑛𝑖𝑖=1 , where 𝑃𝑃𝐼𝐼𝑃𝑃𝑖𝑖 is the posterior 
inclusion probability (PIP) score for variant i in the explored region containing n variants, 
and ∑ 𝑃𝑃𝐼𝐼𝑃𝑃𝑖𝑖𝑛𝑛𝑖𝑖=1  is a summation of PIP score of variants in one region.  It is thus a 
measurement of the support that there is a causal variant in that region.  
3.4 Results 
3.4.1 PolyQTL improves statistical power to find the true causal variants.  
For all simulations, I compared the performance of PolyQTL and an established 
method, DAP. I explored the influence of three factors: heritability of gene expression (0.3, 
0.6), population structure modeled with Fst (0.1, 0.2) and relatedness (0%, 20% of samples 
related as identical twins), resulting in a grid of eight different scenarios. For each scenario, 
I performed 600 simulations. The PIP score of the modeled causal variant was used as a 
measurement of the statistical power to find true causal variants, and different PIP cutoffs 
(0.1, 0.3, 0.5) were used to evaluate the fine-mapping resolution. The PIP score from DAP 
was compared with results from PolyQTL, where improved statistical power is evident 
where the PIP value of causal variants is greater with one method relative to the other. 
 75 
First, I evaluated the performance of PolyQTL in estimating covariance parameters. 
From Figure 3.2, the estimation of genetic components is consistent with the simulated 
values. Simulation results reveal that PolyQTL has performance than DAP. Taking the PIP 
cutoff at 0.1 as an example, in the case of multiple causal variants (n=2), when there is a 
severe population structure (Fst =0.2), if the phenotype has a relatively low genetic 
contribution (heritability=0.3), 73.5% of the PIP scores computed with PolyQTL were 
larger than the cutoff, compared with 66.8% in DAP (Figure 3.3A).  Increasing the 
polygenic contribution (heritability=0.6), PolyQTL had a slightly greater advantage, 75.0% 
vs 65.5% (Figure 3.3C). Furthermore, in the presence of a high proportion of related 
individuals in the samples (20% of samples related), control for relatedness brought 
additional power to find the causal variants, 75.1% vs 63.8% (Figure 3.3D). Similar 
patterns were observed with more conservative PIP cutoffs (0.3 and 0.5). When there is 
Figure 3.2 The parameter estimation of genetic components 
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only a single causal variant, the advantage of PolyQTL is limited, but performance 
improvement relative to DAP is in the range of 1%~5%. 
In the presence of subtle population structure (Fst=0.1), I found that PolyQTL had 
improved performance under conditions of high heritability (0.6), obtaining an 
improvement of 1.0% to 4.7% (Figure 3.4C). Reduction of the heritability to 0.3 resulted 
in weaker improvement, less than 1% (Figure 3.4A,B).  
Even in this case of the absence of population structure or relatedness in the sample, 
PolyQTL has a better performance than DAP and with the increase of heritability, the 
advantage of PolyQTL is more obvious (Figure 3.5). This is because that PolyQTL applied 
a mixed-linear model to estimate the genetic component, and reduced the estimation noise. 
 
Figure 3.3. Comparison of power to detect causal variants between DAP and 
PolyQTL when there are 2 causal variants affecting the phenotype and Fst=0.2. The 
X axis is PIP ranging from 0 to 1, and Y axis is the cumulative distribution quantile 
(Read for DAP, and Blue for PolyQTL). Three PIP cutoff values (0.1, 0.3, 0.5) were 
chosen to compare the rate of discovery of causal variants. (A), (B) are low heritability 
(0.3), and (C), (D) are high heritability (0.6), and 20% of samples were set to be 




Figure 3.4. Comparison of power to detect causal variants between DAP and 
PolyQTL when there are 2 causal variants affecting the phenotype and Fst=0.1. The 
X axis is PIP ranging from 0 to 1, and Y axis is the cumulative distribution quantile 
(Read for DAP, and Blue for PolyQTL). Three PIP cutoff values (0.1, 0.3, 0.5) were 
chosen to compare the rate of discovery of causal variants. (A), (B) are low heritability 
(0.3), and (C), (D) are high heritability (0.6), and 20% of samples were set to be 
identical twins in (B), (D). 
 
Figure 3.5. Comparison of power to detect causal variants between DAP and 
PolyQTL when there are 2 causal variants affecting the phenotype and Fst=0. The X 
axis is PIP ranging from 0 to 1, and Y axis is the cumulative distribution quantile 
(Red for DAP, and Blue for PolyQTL). Three PIP cutoff values (0.1, 0.3, 0.5) were 
chosen to compare the rate of discovery of causal variants. (A), (B), (C) to (D) are the 
results for gradient heritability, ranging from 0.6 to 0.01. 
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3.4.2 PolyQTL has a good control for false positive rate. 
Except for power, another important character of a statistical method is the control 
for false positive rate. To evaluate the performance of the false positive rate control, I 
performed 600 simulations, setting the effect size of causal variant to be 0%, and use a 
measurement, regional PIP, to evaluate the false detection rate. 






PolyQTL DAP PolyQTL DAP 
0.3 
0.9 2/600 6/600 4/600 6/600 
0.8 6/600 10/600 10/600 12/600 
0.6 
0.9 0/600 8/600 2/600 20/600 
0.8 2/600 20/600 2/600 36/600 
The table below (Table 3.1) indicates that both PolyQTL and DAP control type 1 
error well, with an advantage for PolyQTL which becomes stronger both as heritability 
increases and the level of population structure increases. For example, if I choose regional 
PIP 0.9 as the cut-off, on average across the four scenarios only 2 out of 600 null causal 
variants generate a false positive signal, compared with 10 out of 600 with DAP, a five-
fold improvement.     
3.5 Conclusion 
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In this study, I developed a Bayesian multiple eQTL method, named as PolyQTL, 
which can be used to find multiple eQTL regulation in structured populations. I performed 
dense simulations to demonstrate that PolyQTL controls population structure and 
relatedness, improving statistical power to include true causal variants in the list of high 
probability eQTL SNPs.  Meanwhile, PolyQTL also has a reduced false positive rate 




Comprehensive Multiple eQTL Detection and its Application 
in GWAS Interpretation 
ABSTRACT: Expression QTL (eQTL) detection has emerged as an important tool 
for unravelling the relationship between genetic risk factors and disease or clinical 
phenotypes. Most studies focus on analyses predicated on the assumption that only a single 
causal variant explains the association signal in each interval. This greatly simplifies the 
statistical modeling, but is liable to biases in scenarios where multiple linked causal-
variants are responsible. Here, my primary goal was to address the prevalence of secondary 
cis-eQTL signals regulating peripheral blood gene expression locally, utilizing two large 
human cohort studies, each greater than 2,500 samples with accompanying whole genome 
genotypes.  The CAGE dataset is a compendium of Illumina microarray studies, and the 
Framingham Heart Study is a two-generation an Affymetrix dataset. I also describe 
Bayesian co-localization analysis of the extent of sharing of cis-eQTL detected in both 
studies as well as with the BIOS RNA-seq dataset. Stepwise conditional modeling 
demonstrates that multiple eQTL signals are present for ~40% of over 3,500 eGenes in 
both microarray datasets, and that the number of loci with additional signals reduces by 
approximately two-thirds with each conditioning step. Although fewer than 20% of the 
peak signals across platforms finemap to the same credible interval, the co-localization 
analysis finds that as many as 50%~60% of the primary eQTL are actually shared. 
Subsequently, co-localization of eQTL signals with GWAS hits detected 1,349 genes 
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whose expression in peripheral blood is associated with 591 human phenotype traits or 
diseases, including enrichment for genes with regulatory functions such as protein kinase 
activity and DNA binding, and I found that adding non-primary cis-eQTL to conduct co-
localization analysis improves our chance to detect co-localized signals, and contribute to 
10%~40% of significant co-localized results. Just one quarter of these co-localization 
signals replicated, further highlighting the technological and methodological barriers to 
reconciliation of GWAS and eQTL signals. The results are provided as a web-based 
resource for visualization of multi-site regulation of gene expression and is association with 
human complex traits and disease states. 
 
4.1 Background 
Since the first GWAS results were published in 2005 (Klein et al. 2015), thousands 
of genetic regions in human chromosomes have been found to be associated with human 
phenotypes including disease states (Visscher et al. 2017). Since it is now assumed that the 
majority of SNP-trait associations identified by GWAS can be attributed to effects on gene 
expression, precise estimation of the location and effect sizes of regulatory polymorphisms 
has become important for understanding the relationship between genetic and phenotypic 
variation (Maurano et al. 2012; Farh et al. 2015).  The minimal expectation is that eQTL 
analysis can identify the gene within a locus that accounts for a GWAS signal, although it 
has become clear that even this goal is a far from trivial (Chung et al. 2014; Pickrell et al. 
2014).  Many investigators make the stronger assumption that co-localization of regulatory 
variants (eSNPs) and GWAS signals to a tight linkage disequilibrium interval implies the 
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ability to define if not the causal variant, then at least a credible set of SNPs that include 
the causal site(Trynka et al. 2013; Gaulton et al. 2015; Kichaev and Pasaniuc 2015; Liu et 
al. 2015).   
However, high resolution fine mapping eQTL results aligned with GWAS studies 
for diverse phenotypes has as yet provided only a few instances with unambiguous 
evidence that a specific variant affects a human complex trait or diseases through its affect 
on gene expression. Several recent studies have begun to question the presumed identity of 
eQTL and GWAS hits: even though there is a highly significant overlap at the level of the 
locus, it is not so clear that the precise variants are the same. For example, Farh et al (2015) 
estimated that only ~10% of the GWAS hits take function as eQTL despite the vast 
majority of those hits mapping to non-coding DNA.  Similarly, two recent studies of 
autoimmune disease have also argued that only approximately one quarter of examined 
GWAS loci may act as eQTL in the profiled immune cells (Chun et al. 2017; Huang et al. 
2017). Furthermore, work based on GTEx gene expression profiling aiming to integrate 
GWAS and eQTL results found that only a minority of GWAS loci match precisely to 
eQTL, while the diversity of regulatory effects across tissues can complicate interpretation 
(Hormozdiari et al. 2016; Gamazon et al. 2018). These results raise the question of why 
there are so many instances of discordant fine localization: are we simply limited by the 
low statistical power to detect association signals (Udler et al. 2010), is there mis-
estimation of signal strength and location in the case of multiple eQTL per transcript (Zeng 
et al. 2017), or are regulatory effects so cell-type and context-specific that true co-
localization is often missed? In this studies, I will focus on the first two issues by addressing 
the concordance of signals in two large eQTL datasets where the expectation was that, 
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despite technical differences between the platforms, shared cis-eQTL signals at the gene 
level would map to the same credible intervals.  
The detection of eQTL is dependent on the accuracy of two technologies designed 
to estimate transcript abundance (gene expression) and to genotype or impute genetic 
variants. Genotype calling, whether based on gene chip platforms or whole-genome 
sequencing, is thought to be highly accurate and robust (1000 Genome Project Consortium, 
2015), and methods for imputation of missing genotypes are now generally accepted to be 
valid for minor allele frequencies of 0.01 or lower. Constraints on gene expression 
measurement are more problematic, being subject both to the properties of the detection 
method and of the algorithms use to statistically analyze the data. Microarrays, principally 
Illumina- and Affymetrix- based for human studies, have been used widely to measure 
gene expression and have supported the development of expression QTL (eQTL) analyses.  
By far the largest published study is the 12,000 sample Blood eQTL compendium 
assembled by Lude Franke and colleagues (Westra et al. 2013), now approaching 30,000. 
However, the nature of microarray probes provides incomplete coverage of the exons 
within genes, and there are analytical limitations due to dynamic range of quantitative 
detection of expression, with the result that estimates of transcript abundance are strongly 
platform-specific. eQTL artefacts are also known arise due to linkage disequilibrium 
between regulatory variants and  SNPs located with transcript probes.  Nevertheless, well-
powered studies have detected primary eQTL for over half of all expressed genes in blood, 
providing ample opportunity to compare the fine-mapping of these signals (Lloyd-jones et 
al. 2016). 
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A small number of studies have argued for high replicability of eQTL detected on 
the same platform. Genotype-Tissue Expression (GTEx) project discovered eQTLs from 
post-mortem analysis of over 40 tissues, finding extensive sharing of promoter-proximal 
signals for around half the loci. Zhernakova et al (2017) found that 84% of previous cis-
eQTL genes detected with Illumina platform replicated in an RNA-seq data set, the vast 
majority showing the same direction of allelic effect.  Multiple Illumina-based peripheral 
blood studies carried out on different cohorts by different groups have also reported in 
excess of 70% shared signals for eQTL detected at 5% false discovery rates (Zeller et al. 
2010; Lloyd-jones et al. 2016).  However, differences between platforms seem to be much 
larger than expected; for example,  Liang et al found that only between one quarter and one 
third of eQTL association signals in the MRCE Illumina-based study replicated in a 
companion MRCE Affymetrix study (Liang et al. 2013). The differences may in part be 
due to the differential effects of alternative splicing on transcript abundance detected with 
probes that cover one or a few exons (Illumina) or more of the extent of each gene 
(Affymetrix), or to the effects of the normalization and other statistical procedures that are 
used to associate genotypes with transcript abundance estimates. It is also important to 
recognize that what is described as a shared signal based where a genotype associates with 
gene expression in two studies may often simply reflect linkage disequilibrium between 
two independent signals. 
Consequently, methods have been developed to evaluate and fine-map co-
localization signals, whether across gene expression platforms, or between eQTL and 
GWAS signals. Most of the current methods seek to distinguish true co-localization from 
“shared” signal due to linkage disequilibrium. COLOC was one of the first Bayesian 
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methods which evaluates the relative statistical support of each eQTL-GWAS co-
localization hypothesis contingent on LD (Giambartolomei et al. 2014). However, COLOC 
assumes the default model that a single-causal eQTL exists, which implies a strong prior 
that variants taking function as eQTL (or associated with a trait), also affect the trait (or 
expression), potentially leading to false positive co-localization. SMR, or Summary 
Mendelian Randomization, jointly evaluates the strength of eQTL and GWAS signals 
using a procedure known as HEIDI to filter heterogeneity of GWAS and eQTL signals in 
the presence of LD (Zhu et al. 2016). However, SMR is strongly dependent on the accuracy 
of LD inference from a reference panel, and the HEIDI test has been reported to be 
conservative. Another Bayesian method, eCAVIAR, calculates a posterior probability of 
eQTL-GWAS co-localization while allowing for multiple signals in the interval 
(Hormozdiari et al. 2016). The dependencies of all these methods on sample size has not 
been well characterized, and it is found only around 50% agreement between them in 
evaluation of causal variants in a Crohn’s disease study (Marigorta et al. 2017).  
Furthermore, lack of control for population structure or relatedness requires further 
modification when applied to data sets with large sample size.  
In this study, I collected cis-eQTL results from three data sets, and developed a 
statistical pipeline to achieve the following goals: (a) to evaluating the prevalence of 
multiple cis-eQTL regulation in human peripheral blood; (b) to estimate the extent of eQTL 
signal sharing across three expression platform; and (c) to detect co-localization of eQTL 
signals with GWAS hits contingent on the LD at each locus, revealing the possible 
biological regulatory mechanisms linking genetic variants to complex human phenotypes.  
4.2 Materials and Methods 
 86 
4.2.1 Datasets 
I analyzed three different peripheral blood eQTL data sets. The Consortium for the 
Architecture of Gene Expression, CAGE dataset consists of Illumina HT12 v3 microarray-
based gene expression profiles, as well as whole genome genotype information, from five 
research studies: the Brisbane Systems Genetics Study (BSGS, N=926) (Powell et al. 
2012), Atlanta-based Centre for Health Discovery and Well-Being (CHDWB, N=439) 
(Wingo and Gibson 2015) and Emory Cardiology Genebank (N=147, Kim et al. 2014), 
Estonian Genome Centre - University of Tartu (EGCUT) study (N=1065, Schramm et al. 
2014), and the Morocco Lifestyle study (N=188, Idaghdour et al. 2010), for a total of 2,765 
individuals.  IRB approval was obtained for the combination of data into a mega-analysis 
both by the University of Queensland and for each participating site.   
The second dataset from the Framingham Heart Study (FHS) (Huan et al. 2015) 
contains two-generation data generated on Affymetrix genechips. A total of 5,075 
participants with both genotype and gene expression information from the offspring (N = 
2,119, 8th examination) and third-generation (N = 2,956, 2nd examination) cohorts were 
included in this study. Raw genotype and gene expression data were downloaded from 
dbGAP (phs000007.v25.p9) with IRB approval.   
The BIOS RNA-seq summary data was derived from a meta-analysis of results for 
a total of 2,100 participants from four cohorts (Zhernakova et al. 2017): the Cohort on 
Diabetes and Atherosclerosis Maastricht (CODAM, 184 individuals included); LifeLines-
DEEP (LLD, 626 individuals included); the Leiden Longevity Study (LLS, 654 individuals 
included); and the Rotterdam Study (RS, 652 individuals included). I downloaded the 
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summary results of cis-eQTL signals from https://genenetwork.nl/biosqtlbrowser/, so were 
unable to perform the sequential stepwise regression analyses to detect secondary signals. 
4.2.2 Genotype Imputation  
Genotype imputation for the CAGE cohort was performed jointly for the five 
contributing studies to ensure uniformity of assignment of strand identities of SNPs, and is 
described in detail in Lloyd-Jones et al. (2016) and at 
https://github.com/CNSGenomics/impute-pipe. Briefly, the pipeline involved pre-
imputation quality control, and data-consistency checks, imputation to the 1000G reference 
panel with Impute2 (Howie et al. 2012), post-imputation quality control (filtering on 
various data features), and merging of the datasets on common SNPs.  
For the Framingham Heart Study data, there were a total of 6,950 individuals before 
imputation, from which 29 individuals with genotype missing rate ≥5% were removed.  
Subsequently any SNPs with genotype missing rate ≥5% were also removed along with 
SNPs with Hardy-Weinberg test P ≤10-6. Prior to imputation, the genotypes were pre-
phased using shapeit2 (Delaneau et al. 2013) using the “duohmm” parameter to account 
for pedigree information. Each chromosome was divided into 5Mb chunks, incorporating 
the centromere-adjacent region (acen region) into the neighboring chunk, and similarly 
joining any chunk with <200 SNPs into a neighboring chunk. Imputation was performed 
with Impute2 (Howie et al. 2012), using qctool to convert gprobs to gen file format, and 
only SNPs with info value larger than 0.3 were retained for subsequent analyses. The gen 
file was converted to plink file format, and SNPs with multiple information and InDel 
variants were filtered out. The remaining SNPs were further reduced to ~6 million SNPs 
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with >95% call rate across all 5,075 individuals represented by both genotype and gene 
expression data. 
4.2.3 Probe Re-annotation  
Since SNP imputation for the CAGE cohort was based on hg19/GRCH37, whereas 
the Illumina probe annotation was based on hg18/GRCH36, Ire-annotated the probe 
information by mapping the probe sequences to hg19/GRCH37 with BWA (Li and Durbin 
2009), retaining only the uniquely mapped probes. All probe sequences were secondarily 
mapped to the reference genome with BLAT (Kent 2002), and only probe sequences 
uniquely mapped with both methods were determined to be high confidence and 
subsequently used for eQTL detection.  Of a total of 45,931 probes mapped to the reference 
genome, 7,349 probe sequences mapped to multiple regions or remained unmapped, 
leaving 38,582 probes taken forward for the eQTL analyses.  See Table S1 for summary 
statistics. Since it is well-known (Walter et al. 2007) that SNPs in a probe influence 
microarray hybridization, I also discarded 3,856 Illumina probes containing SNPs with maf 
>1% in the 1000 Genomes European sample (Lappalainen et al. 2013). Similarly, SNPs in 
the Affymetrix probesets were also converted to positions in the hg19 assembly by 
applying liftOver (UCSC Genome Browser) to the GPL5188 annotation file downloaded 
from dbGAP, and annotated to the 1000 Genomes.  Any SNP with a maf >1% in the 1000 
Genome European population and located within a probeset was deemed to be potentially 
unreliable, and was included as a covariate during the eQTL estimation steps. Among the 
280,000 core probesets, 35,000 have such SNPs, and 15,368 transcripts contain at least one 
SNP in a probe. 
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4.2.4 Gene Expression Normalization  
The gene expression normalization strategy for CAGE required aggressive 
procedures to account for study-specific biases, as described in detail in Lloyd-Jones LR 
et al. (2017). It consisted of 5 steps: (1) Variance stabilization using the vsn package (Lin 
et al. 2008); (2) Quantile normalization forcing the intensity distribution across all probes 
to have the same shape for all samples; (3) Batch effect correction via linear regression to 
account for known technical effects, such as RNA extraction date, and physical batch; (4) 
Batch effect correction (via principal component analysis, removing the first 10 PC to 
account for unknown confounding procedural, or population-based influences); and (5) 
Rank normal transformation, namely a final transformation of each probe to a normal 
distribution with mean 0 and variance 1. 
For the FHS data, raw gene expression processed by Affymetrix APT software 
(version 1.12.0) was downloaded from dbGAP, log2 transformed, and surrogate variable 
analysis (SVA) (Leek et al. 2012) was used to remove confounding factors, fitting a total 
of 62 surrogate variables by a linear regression model.  Note that the FHS gene expression 
study (Huan et al. 2015) reported results of a different normalization that included fitting 
blood cell counts, which I chose to avoid since a similar procedure was not applied to the 
CAGE data, and because the blood counts were also removed by the SVA fitting. 
4.2.5 Multi-site eQTL Detection  
For this study, local SNPs were stringently defined as SNPs located within 200 kb 
upstream or downstream of the gene (defined as the first TSS and last TES listed in the 
hg19 annotation) containing the probe. Sequential conditional analyses were performed for 
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each probe, and the genes with significant eSNPs were called eGenes. Since both the 
CAGE and FHS cohorts contain family-based data (the former for a quarter of the samples, 
from the BSGS twin study (Powell et al. 2012); the latter for all participants), a mixed 
linear model was used for eQTL detection in GEMMA (Zhou and Stephens 2012), which 
fits a genetic relatedness matrix (GRM) as a covariate alongside fixed genotype effects.  
The multiTrans tool (Joo et al. 2016), which accounts for family structure, was used to 
specify a study-wise false discovery rate of 5% for genes with multiple independent eSNPs, 
which was empirically observed to be approximately P < 10-5.  After first scanning for 
evidence of at least one local eSNP at this threshold, the residuals after fitting the sentinel 
SNP were used for a sequential conditional scan for an independent secondary eSNP. This 
process was iterated until no more signals were observed below P = 10-5.  SNPs in high LD 
with each previously detected signal (r2≥0.9) were also filtered out of each sequential 
analyses.  The effect sizes of each discovered SNP were recorded as the sequential 
conditional estimates.  Subsequently, for the multi-site effect size estimates, all discovered 
independent peak SNPs were fit with the GRM in one mixed model.  However, since the 
GEMMA software does not report the effect sizes of all fixed effects simultaneously, I fit 
the multi-site models with one SNP specified as the target effect, including the other 
significant SNPs, as well as the GRM, as covariates.  This estimation procedure was 
repeated for each included SNP, recording the effect size of the target SNP as the multi-
site effect, noting that the amount of variance explained by each gene’s model is the same 
for all such models. To control the influence of SNPs located in probes in the FHS data, I 
incorporated in-probe SNPs with an LD r2 cutoff 0.75 as covariates during the multi-site 
modeling step. 
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4.2.6 Fine-mapping with PolyQTL  
Fine-mapping to localize causal variants influencing gene expression was 
performed using PolyQTL (Zeng and Gibson, 2018), a modification of DAP (Wen and 
Pique-Regi, 2016) which I developed to account for population structure and ancestry 
during Bayesian localization in the presence of multiple linked cis-acting variants.  I 
incorporated an option for first performing sequential stepwise regression, using the mixed 
linear regression component of GEMMA (Zhou and Stephens, 2012) as above to isolate 
independent QTL. PolyQTL also offers the option to estimate posterior probabilities for all 
eQTL at a locus simultaneously, but this was not performed here owing to the 
computational burden.  
PolyQTL assumes that there is a single causal variant associated with each 
independent QTL, and evaluates the posterior probability, given the LD structure at the 
locus, that each variant in the interval is causal, such that the sum of the posterior 
probabilities for each independent QTL is between 0 and 1. Genes were modeled as being 
under partial control of local genotypes as well as the polygenetic background, expressed 
as y = Xiβi + G + ε, where y is a vector of transcript abundance phenotypes, G represents 
the influence of the polygenic background, Xi and βi are the genotype and effect of the 
explored variant, and ε is a random environmental factor also normally distributed N(0, 
𝑉𝑉𝑒𝑒2). PolyQTL uses REML to estimate genetic and environmental variances, 𝑉𝑉𝑔𝑔2 and 𝑉𝑉𝑒𝑒2 
given the estimated GRM, K (Yang et al, 2010). To remove the influence of population 
structure, we transform the phenotype (y) and genotype (Xi) with the square root of the 
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covariance of the phenotype, (𝑉𝑉𝑔𝑔2�K + 𝑉𝑉𝑒𝑒2�I), where I is the identity matrix, as this results in 
independent multivariate normal distributions. We then compute a posterior inclusion 
probability (PIP) for each variant, leading to a ranking of candidate causal variants (Zeng 
and Gibson, 2018). 
4.2.7 eQTL sharing across expression platforms  
Despite the expectation that expression platform influences eQTL detection, I 
reasoned that cis-eQTL results can complement one another leading to enhanced detection 
of shared signals by overcoming false negative results from single studies.  To this end, I 
performed joint analysis of the cis-eQTL signals obtained on all three platforms, namely 
Illumina, Affymetrix, and RNA-seq. I devised a new method based on the eCAVIAR 
strategy (Hormozdiari et al. 2016), named DPolyQTL, which explores the signal sharing 
for two phenotypes (either molecular traits or phenotype traits) even where the collected 
samples are family-based or from diverse ethnicities. DPolyQTL calculates a posterior 
probability that the causal variants are shared for two phenotype traits, such as expression 
of a gene measured on two platforms, by multiplying the two posterior probabilities 
together to generate a colocalization posterior probability (CLPP: Hormozdiari et al. 2016). 
Since interpretation of the calculated posterior probability as a shared causal 
variants is confounded by the complex LD structure in human genome, I conducted 
permutations to obtain the null distribution of the posterior probability given that a true 
eQTL is detected in one of the datasets, the discovery dataset, is replicated in the other one, 
the replication dataset. To do so, the phenotype was permuted in the replication dataset, 
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and the posterior probability was re-calculated.  On this basis the co-localization signal was 
determined to be true if the CLPP ≥ 0.001 and permutation P-value ≤0.05.  
4.2.8 eQTL and GWAS co-localization analysis   
Summary results were downloaded for 1,263 phenotype traits or disease from 
eQTLgen Consortium. For each trait or disease, I defined candidate independent candidate 
regions as all variants within 100kb of a peak association signal at P ≤5×10-8. To reduce 
the computational burden, I excluded all variants in the interval with P ≥0.05.  
Co-localization of the eQTL and GWAS signals was then assessed for all genes 
located within 1Mb of the peak GWAS signal.  Similar to the analysis of eQTL sharing 
between expression platforms, I conducted DPolyQTL on the GWAS and eQTL summary 
statistics to identify regulatory influences of gene expression on complex phenotypes or 
disease. 
4.3 Results  
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4.3.1 Multiple eQTL regulation is ubiquitous in human blood 
Our first objective was to estimate the proportion of loci that have multi-site 
regulation in the two large cohort studies, CAGE and FHS. Since both datasets include 
siblings, I used GEMMA (Zhou and Stephens 2012) to perform sequential conditional 
eQTL analysis deploying a genetic relationship matrix based on all measured and imputed 
genotypes to model family structure and population structure.  Applying sequential 
conditional analysis to CAGE, I detected 5,974 eGenes (37.8% of 15,812 tested genes) 
with at least one significant eSNP at P < 10-5. Of these eGenes, 2,187 (36.6%) contain 
probes influenced by more than one eSNP and hence appear to be regulated by multiple 
enhancers. (Note that in the case of genes with multiple probes on the Illumina platform, 
Ionly required that at least one probe was associated with an eQTL, and for multi-SNP 
regulation included only the probe with the largest number of significant independent 
eSNPs).  Similarly, in the FHS data, I detected 5,597 (35.3% of 15,853 tested genes), 2,098 
(37.5%) of which were regulated by multiple eQTLs.  In CAGE, the average variance 
Figure 4.1 Detected independent cis-eQTL in CAGE and FHS cohort. 
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explained by detected eSNPs was 6.1%, the same as in FHS, 6.1%, and in both cases these 
estimates account for more than half of the previously estimated cis heritability (Lloyd-
Jones et al, 2017). For those genes with multiple eQTL regulation in CAGE, which have a 
mean explained variance of 7.2%, the newly detected secondary eSNPs typically explained 
20% more variance than the peak SNP alone, namely ~1.2% of the phenotypic variance 
(6.0% vs 7.2%), also in line with estimates from Lloyd-Jones et al. (2017). For eGenes 
with multiple eQTLs in FHS, the mean explained variance is 6.3%, and the secondary 
signals increase the explained variance from 6.5% to 8.3%, an ~28% increase.  
 
Table 4.1. Cross-platform comparison of eSNP detection after adjustment for 
probe SNPs 
             
                                           With SNPs-in-Probes             Without SNPs-in-Probes 
No.         CAGE  FHS    Both_any       CAGE FHS  Both_any    Both_highLD# 
             
≤ 1 3175 3874 1330 3787 3499 1186   474 
≤ 2 5571 5989 1685 5246 4699 1442   616 (34) 
≤ 3 6113 6929 1777 5733 5182 1518   669 (7) 
≤ 4 6280 7327 1805 5881 5407 1539   686 (1) 
> 0 6383 7713 1812 5974 5597 1565   689 (0) 
             
# Cumulative number of eGenes with at least 1 eSNP localized within r2 > 0.8 in both CAGE and FHS, 
number in brackets indicates cases with 2, 3, or 4 eSNPs all in high LD between datasets. 
      Figure 4.1 shows frequency histograms for the number of detected eQTL per 
gene after each sequential step in both studies: the number of loci with additional 
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independent sites reduces by approximately two thirds with each additional SNP in both 
CAGE and FHS, up to half a dozen variants, and a few loci have 10 sites. This reduction 
likely reflects the true prevalence of multi-site effects as well as reduced power to detect 
SNPs that explain less of the variance than the primary signal.  A detailed example of multi-
site association is shown for the HBZ locus in CAGE (Figure A4.1), where from left to 
right, and top to bottom are the results of stepwise conditional analysis yielding 9 
independent eQTL signals. The total explained variance is 39.8%, one third more than the 
28.4% explained by the highest single-site signal.  An example from the FHS is ABHD2 
where I detect 5 independent eQTLs explaining 9.3% of the variance, compared with 5.6% 
for the peak eSNP (although the Affymetrix probeset contains a common variant, 
rs2283435, that is in linkage equilibrium with each of the five regulatory signals). All of 
the multiple eQTL results can be downloaded both in tabulated format and as locuszoom 
plots from Prof. Gibson’s lab server at given URL. 
      I also computed the difference between the estimates fitting all discovered 
variants jointly and the conditional single-site estimates following eSNP sequential 
conditional discovery.  The average change in estimated beta was 0.04 sdu, plus or minus 
0.06 due to a long tail of large deviations.   
To compare directly the degree of signal replication from cohorts based on a same 
platform, I also evaluated the level of replication between the contributing studies in 
CAGE.  For examples, contrasting eQTL detection for chromosome 1 genes between 
the CHDWB and EGCUT cohorts at FDR<=0.01, I detected 665 significant independent 
eQTL in EGCUT, and 364 in CHDWB, 315 of which (86.5% of the peak eSNPs) located 
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in the same credible interval (genotype r2>=0.8).  This result further validates the mega-
analysis strategy of combining the different CAGE study cohorts into one large study. 
4.3.2 A Bayesian fine-mapping approach increases the power to detect cis-eQTL sharing 
4.3.2.1 The r2 criterion results in poor overlap of cis-eQTL between CAGE and FHS. 
      Direct comparison of primary results from the CAGE and FHS analyses 
suggests a disappointingly low level of replication. Primary peaks in CAGE were detected 
for 53.0% of the eGenes represented in the FHS, and reciprocally 56.5% of the FHS eGenes 
had primary signals in CAGE, very similar to the proportions reported for eSNPs at P < 
10-8 across four peripheral blood studies (Zeller et al. 2010) that also had a variety of 
technical differences.  However, the overall overlap between CAGE and FHS for eSNPs 
within credible intervals defined by LD r2>0.8 is just 29.1%. Furthermore, only 41.5% of 
the primary signals in FHS are in LD (r2>0.8) with the primary eSNP in CAGE, suggesting 
that different largest-effect regulatory variants are tagged in the two datasets. This overall 
eSNP replication rate was slightly higher (47.2%) when mapping to 1,314 probesets which 
map directly to the same exon and have an eQTL signal on both platforms.   
     The replication rate of secondary, tertiary, and quaternary signals in FHS 
irrespective of LD was just 19.0%, 11.3%, and 11.0%, indicating successive decay, likely 
due to reduced power for weaker signals.  The reasons for the discrepancies between the 
studies may have to do with collapsing of probe-level data down to gene-level signals 
losing information on splice isoforms, the different normalization strategies (which alone 
can double discovery rates (Qin et al. 2012)), and cross-study biological heterogeneity. 
Comparison of the percent variance explained by discovered SNPs on the two platforms in 
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Figure A4.3 shows that effect sizes for many genes are disproportionately tagged by eQTL 
in the two studies, implying platform effects.   Among 139 genes with more than 20% of 
the variance explained by cis-eSNPs, the replication rates are 64.7% for the primary signal, 
34.8% for the secondary, 14.4% for the tertiary, and 8.5% for the quaternary. The 
subsequent panels confirm that all of these replication rates are proportional to the percent 
variance explained overall, confirming that statistical power is a major source of low 
replication. 
 99 
For the HT12 v3 Illumina probes, 10% of the uniquely mapping probes contain at 
Figure 4.2 An example of shared cis-eQTL signals in CAGE and FHS. I detected 
two cis-eQTL for ORMDL3 in both CAGE and FHS. For CAGE, two independent 
rs12936231, and rs17608925 were found to be associated with expression abundance. 
In FHS, rs17608925 was detected to be independent peak signal, while another 
independent peak variant, rs8067378 was detected. The genotype r2 is 1 between 
rs12936231 and rs8067378. 
Figure 4.3 An example of rank-changed cis-eQTL signals in CAGE and FHS. I 
detected two cis-eQTL for ORMDL3 in both CAGE and FHS. For CAGE, two 
independent rs2158799, and rs498475 were found to be associated with expression 
abundance (Panel A). In FHS, I detected a primary signal, rs849333, which locates in 
high LD with the secondary signal rs498475 in CAGE (genotype r2=0.90), while 
another independent peak variant, rs563289 was also detected (Panel B). 
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least one SNP with MAF>1% in 1000 genome European population.  The prevalence of 
eQTL was twice as great for these probes (59% versus 30% of 23,681 “clean” probes), so 
Ijust removed the Illumina probes containing SNPs in order to control the false discovery 
rate. However, since most of the Affymetrix probesets contain at least one SNP, this was 
not practical for the FHS dataset and instead I employed a conditional analysis strategy 
incorporating SNPs in probes as covariates.  For ~15,000 detected eSNPs, one third of the 
association signals were abrogated by conditioning on the SNPs in probes, and the number 
of eGenes correspondingly reduced by 25%.  Table 1 contrasts the eQTL results from both 
platforms before and after controlling for the SNP-in-probe effects.  The first three data 
columns show the cumulative number of eGenes with at least 1, 2, 3, 4, or more detected 
eSNPs before SNP-in-probe removal, and the next three show the cumulative numbers 
after.  The proportion of overlapping signals is not greatly affected.  The last column shows 
that the number of eGenes where at least one detected signal is likely capturing the same 
variant is around 44% (689/1565), and that the number where all of the multiply detected 
signals are within r2 > 0.8 is very small.  There are 214 genes with at least two signals in 
high LD with one another. 
4.3.2.2 DPolyQTL increases the proportion of cis-eQTL sharing across different 
expression platforms 
Next, I used DPolyQTL to enhance the power to detect shared cis-eQTL credible 
intervals in the CAGE, FHS, and BIOS datasets. I extracted each locus by considering 
variants locating in high LD with the reported peak variants in each eQTL study, and 
calculated a posterior probability to demonstrate the the likelihood that each variant 
influences the trait controlling for LD at the locus. Since the available BIOS dataset only 
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consists of summary results, it was used solely as a discovery dataset. Where genes in 
CAGE and FHS contained multiple probes or probe-sets, replication is reported where at 
least one probe in each dataset contains a signal. 




Illumina CAGE - 62.60% 
Affymetrix FHS 53.30% - 
RNA-seq BIOS 44.70% 54.50% 
Tables 4.2 reports the cis-eQTL sharing among CAGE, FHS, and BIOS datasets. 
Shared signals are indicated for 62.6% of the detected cis-eQTL of CAGE in FHS, and for 
53.3% of the FHS eGenes in CAGE. For the detected cis-eQTL in BIOS, I found a similar 
replication rate, namely 53.6%, and 54.7%. Considering that BIOS only reports the eGenes 
and that for some genes no expression information available in CAGE and FHS, the 
replication rate considering all genes is 44.7% in CAGE, and 54.5% in FHS.  Since 
DPolyQTL is statistically flexible, it allows multiple eQTL signals to be explored 
simultaneously. On this basis, 43%~49% of primary eSPNs showed evidence for 
replication, but the rate was considerably lower, only ~10%, for secondary eSNPs. 
Taken together these results indicate greater than 50% cross-platform replication of 
eGenes across platforms, with evidence that the majority of primary eQTL detected on one 
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platform are also eQTL on another.  However, the primary regulatory variant maps to a 
different credible interval in more than a third of the cases, and replication of secondary 
variants is strongly reduced by low statistical power in the presence of multisite regulation. 
4.3.3 Biological Annotation of detected multiple eQTLs 
Since chromatin marks are often used to enhance fine-mapping, on the basis that 
peak eSNPs are enriched in the vicinity of ENCODE features such as DNAse 
hypersensitivity, methylation, and histone modification, I asked whether there is a 
difference in functional attributes of primary and secondary eQTL.  The CADD and 
deltaSVM scores are two commonly used annotation tools that summarize multiple types 
of functional evidence. For the CADD score, to determine the significance of enrichment, 
I created a list of background SNPs with similar allele frequency in the neighboring regions 
and compared the annotation of eQTLs with that of background SNPs. The distribution of 
CADD scores was significantly higher for the reported-peak variants, suggesting elevated 
Figure 4.4 Biological annotation for the detected cis-eQTL signals. 
C D 
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likelihood that they are pathogenic and typically selected against (figure 4.2A for CAGE, 
2B for FHS).  However, although significant, the magnitude of the effect is small relative 
to the variance in CADD scores and the positive predictive value for each SNP is low.  
Similarly, potential causal variants defined with the fine-mapping step have slightly 
elevated probability of locating to regulatory enhancers in human genome defined by the 
deltaSVM score.  Setting any variant with a posterior probability ≥0.8 as a causal variant, 
I found that there is a significant positive relation between the reported beta value and 
deltaSVM (P ≤10-6 in both CAGE and FHS, figure 4.2C, 4.2D), though again the overall 
correlation is weak. 
4.3.4 Interpretation of GWAS results 
4.3.4.1 eGenes associated with phenotypes are enriched for certain molecular functions  
In this section, I aimed to identify genes whose expression also associates with 
phenotypic traits reported in dbGaP. I combined the full summary statistics of 1,263 
GWAS results with eQTL signals from CAGE, FHS, BIOS, maximizing statistical power 
Figure 4.5. Replication of eQTL-GWAS co-localization with different expression 
platform 
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by performing co-localization analysis based on cis-eQTL detected on all three platforms. 
This co-localization analysis resulted in 1,349 genes associated with 591 human complex 
phenotype traits or disease (49. 8% of explored).  The highest single platform discovery 
rate was for the CAGE data on the Illumina platform, and the replication rate across 
platforms ranged from 24% to 30% (Figure 4.5).  
Enrichment analysis with the PANTHER database (Mi et al, 2016) revealed that 
genes annotated to protein kinase activity or to DNA binding activity were over-
represented. PANTHER Pathway analysis further showed that genes involved in  
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (4.2 
fold enrichment, 8.5×10-4), VEGF signaling pathway (3.2 fold enrichment, 4.4×10-4), 
Interleukin signaling pathway (3.1 enrichment, 8.6×10-5), Ras Pathway (2.7 fold 
enrichment, 2.4×10-3), PDGF signaling pathway (2.3 fold enrichment, 6.0×10-4), 
Gonadotropin-releasing hormone receptor pathway (2.0 fold enrichment, 7.2×10-4), and 
Inflammation mediated by chemokine and cytokine signaling pathway (1.92 fold 
enrichment, 1.1×10-3), were enriched. Furthermore, these 1,349 detected genes were 
enriched for association with several disease, 327 causing Mendelian diseases (1.4 fold 
enrichment to background, p=8.6×10-7), providing further evidence that genes defined by 
highly penetrant mutations also harbor quantitative regulatory variants that influence 
disease.  
4.3.4.2 Co-localization detects known and novel eGenes affecting phenotype and disease  
The co-localization results highlight a number of genes that have been reported to 
affect phenotypic traits through gene expression. For example, I found 5 genes associated 
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with coronary artery disease, PSRC1, IL6R, LIPA, SWAP70, and VAMP8 (Figure 4A) in 
the CAGE dataset. Four of these genes have previously been reported to be associated with 
coronary artery disease. PSRC1 encodes a cysteine protease which has been associated 
with HDL and LDL levels (Kathiresan et al, 2008), and its expression in mouse liver is 
significantly associated with plasma LDL cholesterol level (Schadt et al, 2008). LIPA 
encodes lipase A, which catalyzes the hydrolysis of cholesteryl esters and triglycerides, 
and in previous studies, it is associated with CAD, where the lead CAD risk allele correlates 
with increased expression of LIPA mRNA in monocytes (Zeller et al, 2010) and liver 
(Coronary Artery Disease Genetics Consortium, 2011). SWAP70 encodes a signaling 
molecule involved in the regulation of filamentous-actin networks in cell migration and 
adhesion. An intronic SNP has been reported to be a cis-eQTL in naïve and challenged 
monocytes (Nikpay et al, 2015). Notably, rheumatoid arthritis has been associated with 
cardiovascular disease prevalence, yet there is little genetic support for this relationship. I 
found that expression of the IL6R gene is associated with both rheumatoid arthritis and 
coronary artery disease. I also found that co-localization signals from different expression 
platforms complement one another, and can capture more biological insights. Thus, with 
FHS gene expression, there are 11 genes also associated with CAD: ADAMTS7, CARF, 
CDKN2A, GGCX, HECTD4, IL6R, LIPA, PCSK9, PSRC1, USP39, VAMP8, including 
four of the CAGE genes (IL6R, LIPA, VAMP8, and PSRC1). Of the remaining genes, 
manual review of the literature finds that 5/7 have been reported to be associated with 
CAD.  
Our co-localization analysis also identified genes relevant to multiple linked traits 
or diseases. In previous studies, IKZF3 was reported to affect the autoimmune diseases 
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Crohn’s disease, ulcerative colitis and rheumatoid arthritis. These findings are replicated 
in my data, and enhanced further by associations with the additional autoimmune diseases, 
type 1 diabetes, and primary biliary cirrhosis as well as with asthma (Figure 4.4B). 
Expression of IKZF3 is also associated with neutrophil cell and white blood cell counts.  
Most of these co-localization signals are replicated in FHS or BIOS data. 
 
4.3.4.3 Gene expression regulated by non-primary cis-eQTL mediates genetic effect to 
phenotype and disease 
In previous co-localization studies, it is reported that only limited proportion of 
GWAS variants take function as eQTL (Farh et al. 2013; Chun et al. 2017). However, those 
studies mainly focus on primary cis-eQTL. I expect that co-localization analysis based on 
additional eQTL should increase our chance to find the co-localized eQTL-GWAS signal. 
For each expression-phenotype pair with at least significant co-localized signal, I first find 
variants showing sign of colocation in the credible interval of primary cis-eQTL, and if 
Figure 4.6 Two examples of eQTL-GWAS co-localization. One example is that 
IKZF3 is previous reported to be associated with diverse auto-immune diseases. In 
my analysis, I not only replicated previous findings, and also found the association 
with other auto-immune diseases and some immune-associated phenotype traits. 
Another is for the detected genes whose expressions were demonstrated to affect 
CAD.  
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variants are found, I assert that the co-localization results from primary cis-eQTL. If none 
variant is found, then switch to secondary cis-eQTL, tertiary signals, so on and so forth 
until no cis-eQTL remains. 
For 2,138 co-localized signals in CAGE, I detected 82.0% of the co-localized 
signals are from primary eQTL, and 11.0% from secondary signals, 3.9% from tertiary 
signals. In FHS, there are 958 co-localized eQTL-GWAS, 69.5% are from primary signals, 
and 15.1% from secondary signals, and 11.9% from tertiary signals. For instance, like 
shown in Figure 4.3, I detected two independent cis-eQTL, rs2158799 and rs498475 for 
JAZF1 in CAGE, and the secondary cis-eQTL, rs498475 locates in high LD (r2=0.92) with 
a type 2 diabetes GWAS hit, rs849135, and co-localization analysis does find a significant 
signals. The co-localization results indicate a great contribution of non-primary cis-eQTL. 
4.3.5 eQTLHub: A R application based on shiny package to visualize the multiple cis-
eQTL results, and the co-localization signals of eQTL-GWAS. 
To present the multiple eQTL results, I developed eQTLHub, a website based on 
the shiny package for visual exploration of eQTL signals in human blood tissue. There are 
four components, eQTL signal, candidate list for causal variants, eQTL sharing, and 
GWAS-eQTL Co-localization. 





In summary, I find extensive evidence for secondary and tertiary cis-eQTL 
associations explaining gene expression variation in peripheral blood. At least a third of all 
highly expressed genes display such effects, consistent with recent evidence from very 
large-scale GWAS that at least one quarter of loci harbor multiple associations within a 
Mb interval. However, the fine mapping of eQTL across platforms is considerably lower 
than expected and accordingly replication of co-localization with visible phenotypes and 
disease risk is also modest, despite the large sample size of my two cohorts. Since 
secondary and tertiary effect sizes are generally smaller than primary ones, statistical power 
remains a major detriment to the joint fine mapping of regulatory variants to GWAS 
credible intervals. 
Resolution of GWAS associations to single causal variants is a major current 
objective of human genetics.  Four general strategies are being deployed: very large GWAS 
and eQTL studies, including cross-population analyses, intended to narrow peaks; 
sophisticated co-localization approaches; filtering on functional attributes associated with 
SNPs; and high-throughput experimental validation.  The first objective is to define 
credible intervals that are highly likely to contain the causal variant or variants within a 
linkage disequilibrium block.  However, several recent studies have reported that as few as 
one third of disease associations map to the same credible interval as the lead eQTL, even 
in cases such an autoimmune Crohn’s disease where the eQTL mapping is carried out in 
the presumably relevant peripheral blood tissue consisting of immune cells (Huang et al. 
2017; Chun et al. 2017). 
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Two classes of explanation may account for this discrepancy between expectation 
and observation: biological and technical.  The obvious biological explanation is that the 
causal variant detected by GWAS for some phenotypic trait does not directly regulate gene 
expression.  It may for example influence chromatin structure, preparing the locus for 
induction under conditions not sampled in the transcriptomic study (Alasoo et al. 2018), 
and indeed there is some evidence for greater overlap of methylation QTL than expression 
QTL with Crohn’s disease associations (Huang et al. 2017).  A corollary would be that the 
influence on gene expression would only be seen if the appropriate tissue (or the most 
important cell type within a mixture of cell types, such as peripheral blood) is sampled, or 
under more appropriate conditions of stimulation either ex vivo or in vivo (such as inflamed 
tissue-resident immune cells).  The prevalence of response-eQTL provides good evidence 
in support of this claim (Fairfax et al. 2014). 
Technical explanations relate to statistical methodology and power, as well as 
platform effects.  It is remarkable in my study that both the Illumina and Affymetrix 
datasets yielded very similar proportions of eGenes, as well as distributions of secondary 
and tertiary signals.  Yet the overlap between these signals was only approximately one 
half for the primary eSNPs, and less than 20% for conditional associations.  
Implementation of DPolyQTL provided evidence that statistical power is a major source 
of failure to replicate, both by enhancing the detection of shared primary signals between 
the datasets and showing that detection rates drop as effect sizes of secondary, tertiary and 
quaternary associations reduce.  Nevertheless, it is also clear that platform effects result in 
major differences in blood cis-eQTL detection.  These are only partially ameliorated by 
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focusing on probes that capture the same exon within a transcript, implying that detection 
of alternate splicing and isoform usage is just one aspect of the platform effect. 
Irrespective of the causes of differential localization of primary eSNPs, an 
important practical implication of my findings is cautioning against the common use of 
summary eQTL statistics as evidence that a GWAS hit acts as an eQTL.  Given the 
extensive linkage disequilibrium typically observed over long stretches of regulatory DNA, 
it is not uncommon for the GWAS variant to be included in a list of eQTL highly significant 
summary statistics listed on browsers such as the Blood eQTL browser.  Visual inspection 
of the profile of association across the locus will often be sufficient to illustrate that the 
eQTL and GWAS peaks are not actually the same.  Formal tests of the hypothesis of 
equivalence are provided by software tools such as COLOC, but these are designed for 
supervised analysis locus-by-locus and may be biased by the assumption that a single 
causal variant is responsible for each eQTL effect.  The HEIDI test in SMR attempts to 
adjust the inference that an eQTL mediates the phenotypic association for local LD, 
providing genome-wide estimation of cases of heterogeneity of effects.  Alternatively, the 
Bayesian eCaviar approach, implemented here in DPolyQTL to adjust for population 
structure and familial relatedness, more directly adjusts for LD in the derivation of 
posterior probabilities of joint association.  I recommend using a combination of these 
approaches to explore the likelihood that eQTL explain GWAS effects, and to this end have 
developed a web browser which for the first time allows users to explore the profile of 
primary and secondary signals in peripheral blood. 
Contrary to the expectation that mega-analysis of large eQTL studies would 
improve the resolution of eQTL signals, I instead find levels of complexity that complicate 
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the ability to reduce genetic associations to single causal variants.  Most clearly, it is 
apparent that multiple regulatory variants affect the expression of the majority of 
transcripts expressed in peripheral blood.  Similarly, meta-analysis of GWAS including 
hundreds of thousands of individuals increasingly find secondary associations at individual 
loci (Wood et al. 2014; GIANT Consortium, 2018). I have previously shown by simulation 
that the presence of multiple variants in LD blocks typical of human genes biases both the 
localization of eSNPs and the estimation of their effect sizes, with as many as 20% of 
effects potentially located outside detected credible intervals (Zeng et al. 2017).  While 
functional data collected by the ENCODE project and measures of evolutionary 
conservation are often used to filter or adjust eQTL estimation, my analyses only confirm 
a modest enrichment of such marks at eQTL peaks.  Elsewhere it is shown that this is in 
large part due to the high correlation of functional scores within credible intervals (Liu et 
al. 2018).  Consequently, functional assays will continue to provide the gold standard for 
demonstration that specific SNPs associate with trait function through gene regulation. 
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CHAPTER 5  
Trans-eQTL detection in the FHS cohort and cis-trans eQTL mediation 
analysis 
ABSTRACT: Although cis-eQTL have been demonstrated to be powerful in interpretation 
of GWAS results, it can only provide local regulation information, while trans-eQTL can 
be used to find downstream genes and perform gene network analysis. However, trans-
eQTL detection has been blocked by the fact that trans-eQTL have smaller effect size, and 
also the huge burden of multiple test correction. In this analysis, I applied a statistical 
strategy based on mixed linear model to conduct trans-eQT detection. Results reveal that 
the method has a good control for false positive, and the detected trans-eQTL have a 
consistent estimation with other results based on large sample size studies. Comparisons 
of eQTL signals among expression platform found that cis-eQTL detection is more easily 
affected by platform-specific factors than trans-eQTL.  Co-localization analysis reveals 
that most trans-eQTL take function as cis-factor on the local genes to affect downstream 
gene expression.  
 
5.1 Background 
The advance of high-resolution genotyping technology has led to a wave of 
genome-wide association studies (GWAS) of hundreds of phenotypes relevant to human 
health and disease. Yet, the vast majority of detected hits from GWAS significantly 
 113 
associated with clinical traits and disease states locate in non-coding regions, and are 
assumed to function as regulatory factors instead of changing protein function. Thus, to 
improve understanding of biological mechanisms, exploring the relationship between 
genetic variants and RNA expression abundance is a critical step toward ultimate 
improvements in diagnosis, prevention, and treatment of disease. This endeavor begins 
with analysis of variation in messenger RNA (mRNA) expression levels associated with 
genotypic variation to identify expression quantitative trait loci (eQTLs) across the human 
genome.  
Statistical methods in eQTL detection are similar to those used in GWAS, and the 
statistical strategies developed for GWAS can be directly applied for eQTL studies. 
However, eQTL detection involves thousands of genes and hundreds of thousands variants, 
or even millions of variants after imputation. For cis-eQTL, analysis is simplified because 
only several hundred or thousand variants are used and effect sizes tend to be large, while 
for trans-eQTL, there is not only a greater computational burden, but control for multiple 
test correction reduces statistical power. For these reasons, currently only cis-eQTL are 
widely explored, and trans-eQTL detection has lagged behind. A consortium of researchers 
is needed to collect a large sample size to gain statistical power for trans-eQTL analysis.  
In contrast to cis-eQTLs, analysis of trans-eQTLs is vastly more computationally 
challenging and reported trans-eQTLs have proven to be less replicable across studies. 
Therefore, many eQTL studies focus only on cis-eQTLs or a subset of variants associated 
with phenotypic traits or important biological functions. However, according to results 
from studies estimating gene expression heritability (Lloyd Jones et al, 2017), at least half 
of expression heritability can be accounted for by trans-eQTL factors. When SNPs at a 
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trans-eQTL locus affect the expression of multiple genes, the region is usually referred to 
as a trans-eQTL hotspot. Cis-eQTLs typically reside close to transcription start sites 
(TSSs), suggesting that they directly impact gene expression. The mechanisms by which 
trans-eQTLs alter transcription of their linked trans-eGenes are largely unknown and likely 
often reflect indirect or cryptic regulation. For example, it has been proposed that 
expression of trans-eGenes could be mediated by transcription factors encoded by genes 
located close to the corresponding trans-eQTLs. This phenomenon suggests that cis-eQTLs 
might influence the expression of master regulators for a large number of trans-eGenes, in 
the manner of biological networks.  
In this chapter, I report results of an Affymetrix microarray-based genome-wide 
eQTL study, considering both cis and trans elements, in whole blood samples from over 
5000 participants in the Framingham Heart Study (FHS), a multi-generational community-
based prospective study. In this analysis, I aimed to ascertain to what extent SNPs affect 
genes in cis and in trans and to determine whether eQTL mapping in peripheral blood could 
identify downstream pathways that might be drivers of disease processes. 
5.2 Material and methods 
5.2.1 Study cohort 
The Framingham Heart Study (FHS) is a cohort study initiated in 1948, with the 
aim of identifying risk factors for heart disease. Starting in 1971, the offspring and 
offspring spouses (N = 5,124) of the original FHS cohort participants were recruited and 
they have been examined approximately every 4 years since. From 2002 to 2005, the adult 
children (third generation cohort, N = 4,095) of the offspring cohort participants were 
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recruited and are also being examined in an ongoing manner. For this study, a total of 5,075 
participants who provided both genotype and gene expression information from the 
offspring (N = 2,119) and third-generation (N = 2,956) cohorts were included. Whole blood 
samples were collected at the eighth examination of the offspring cohort and the second 
examination of the third generation cohort. Fasting peripheral whole blood samples (2.5 
ml) were stored in PAXgeneTM tubes (PreAnalytiX, Hombrechtikon, Switzerland) and the 
Affymetrix Human ExonArray ST 1.0 (Affymetrix, Inc., Santa Clara, CA) was utilized to 
measure mRNA expression levels. Genotyping was performed with the Affymetrix 500K 
mapping array and the Affymetrix 50K gene-focused MIP array. Genotype imputation was 
conducted using impute2 against 1000 Genomes Phase 3 reference. 
5.2.2 Trans-eQTL Detection Pipeline for FHS 
Imputation results were converted to bgen format with genotype dosage as 
independent variables. A genetic relatedness matrix was constructed using all of the 
imputed genotypes using GEMMA (Zhou et al., 2012). For the gene expression data, the 
first 20 non-genetic PCs of gene expression were regressed out, and residuals were used as 
adjusted phenotypes for the association studies.  
Prior to trans-eQTL detection, cis-eQTL were first detected by stepwise sequential 
conditional analysis. Variants located within a distance of less than 1Mb from either the 5’ 
or 3’ ends of the explored gene coding region were deemed to be cis, and only SNPs with 
a minor allele frequency (MAF) of >0.01 and a Hardy-Weinberg equilibrium P value of 
>0.001 were included in the analyses. In each iteration of the conditional analysis, the peak 
signal with a P value<10-6 also computed using the GEMMA package, was determined to 
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be an independent eSNP. The residuals from discovery of each SNP were then taken 
forward as the dependent variable in a new scan for additional independent SNP(s).  
After cis-eQTL detection, residuals removing all cis-eQTL effects at each gene 
were used as the phenotype, and trans-eQTL detection was performed on 10,562 variants 
previously shown to be associated with phenotypic traits.  The signal was evaluated with a 
mixed linear model in GEMMA, controlling for population structure and relatedness. To 
obtain the null distribution by permutation, the covariance component was firstly estimated 
by REML, and the square root of the covariance matrix was used to transform the 
phenotype and genotype matrices (Abney et al., 2002), after which, the transformed 
phenotype is exchangeable, and can be safely used to conduct permutation analysis. The 
false discovery rate was controlled relative to 10 phenotype permutations, retaining the co-
expression structure by permuting the sample IDs which were used in common for all 
expression phenotypes. 
5.2.3 Effective Population Size Estimation 
As one of the cohorts in the eQTLGen consortium, my trans-eQTL results were 
integrated into the final meta-analysis results. The Framingham Heart Study was the only 
dataset in the study which did not consist of unrelated individuals but was instead a family-
based cohort. Although the analysis strategy took family relationship into account, I needed 
to determine the effective sample size to use the proper weight for this dataset in the 
weighted Z-score meta-analysis. For a specific variant, the effective population size can be 
calculated with the formula:  
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Neff =  
𝑣𝑣𝑣𝑣𝑣𝑣(𝑦𝑦)−2𝑝𝑝𝑖𝑖(1−𝑝𝑝𝑖𝑖)𝛽𝛽𝑖𝑖
2
2𝑝𝑝(1−𝑝𝑝)∗𝑣𝑣𝑣𝑣𝑣𝑣(𝛽𝛽�) ,  in which, p is the minor allele frequency of the explored variant, 
and 𝑣𝑣𝑣𝑣𝑣𝑣(?̂?𝛽) is the variance of the estimator. The effective population size of one gene can 
be estimated with the mean or median Neff of genome-wide variants by:  





    or 
Formula 2: 𝑁𝑁𝑒𝑒𝑒𝑒𝑒𝑒 = 𝑀𝑀𝑀𝑀𝑀𝑀𝑖𝑖𝑣𝑣𝑀𝑀(𝑣𝑣𝑣𝑣𝑣𝑣(𝑦𝑦) − 2𝑝𝑝𝑖𝑖(1 − 𝑝𝑝𝑖𝑖)𝛽𝛽𝑖𝑖2]/[2𝑝𝑝𝑖𝑖(1 − 𝑝𝑝𝑖𝑖)𝑆𝑆𝑖𝑖2), i ∈{1,2,…,m}     
is the SNP index. 
I selected 20 random genes and used eQTL effects for genome-wide SNPs to 
estimate the effective sample size (𝑁𝑁eff). 
5.2.4 Trans-cis eQTL Co-localization Analysis 
I used cis-eQTL results from 31,684 blood samples and a subset of variants that are 
associated from the trans-eQTL data for the 4,339 FHS samples to evaluate the co-
localization between cis-eQTL and trans-eQTL signals. A total of 4,397 independent trans-
eQTLs were each treated as a single eQTL. As to the cis-eQTL signals, cis-eQTL genes 
were only included in the coloc analysis if they had more than 200 variants shared with 
tested trans-eQTL. Next, I used eQTLGen meta-analysis Z-scores, allele frequencies and 
sample sizes to estimate beta and var(beta), using equations outlined in the Supplementary 
Text of (Zhu et al., 2016). In the formula, approximate sample sizes of 31,000 for cis-
eQTLs and 4,300 for trans-eQTLs, together with minor allele frequencies from eQTLGen 
(without Framingham Heart Study cohort) were used. To test for co-localization, the coloc 
v3.1 package (Giambartolomei et al., 2014) was used with default priors (1×10-4 for both, 
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cis- and trans-eQTL, and 1×10-5 for sharing of eQTL signals). As cis-eQTLs were 
regressed out from expression matrices prior to trans-eQTL mapping, I expected that co-
localization signals would be unlikely to reflect spurious correlation between cis- and trans-
eQTL genes caused by unknown confounders. 
I downloaded curated Gene Ontology gene sets (2018. year version) (Ashburner et 
al., 2000; The Gene Ontology Consortium, 2017) from the Enrichr web site (Chen et al, 
2013; Kuleshov et al, 2016). Those gene sets were used to conduct hypergeometric over-
representation analyses as implemented into the R package ClusterProfiler (Guangchuang 
et al., 2012), while using all the cis-eQTL genes showing co-localization with any trans-
eQTL (coloc PH4>0.8) as a test set and all the cis-eQTL genes included to the co-
localization analysis as the background.  
5.3 Results 
5.3.1 Most of trans-eQTL variants affect neighboring genes. 
Co-localization was tested between the subset of 10,683 cis-eQTL genes and 2,950 
trans-eQTL genes. In summary, 181,821 co-localization tests were conducted between a 
cis-eQTL and a GWAS locus with a trans-eQTL, of which 2,776 resulted in H4>0.8 (Coloc 
hypothesis 4, posterior probability of one causal SNP explaining both the eQTL and 
GWAS signals), suggesting that the cis-eQTL gene mediates the trans-effect in 1.5% of all 
such comparisons.  
418 of the cis-eQTL genes (4%) have at least one downstream gene co-localizing 
with H4>0.8, suggesting cis-trans co-localization for an average of 6.6 such targets per cis- 
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eQTL (compared with 0.26 per all tested cis-eQTLs).  Some of the cis-eGenes have as 
many as 100% of the potential targets significant.   1,528 of the trans-eQTL genes (52%) 
have at least one cis-eQTL gene with a colocalizing eQTL effect (H4>0.8), strongly 
suggesting possible cis-trans co-localization, an average of 1.8 cis-mediators per trans-
eQTL (compared with 0.9 per tested trans-eQTLs). No more than 33% of the potential 
mediators for any given trans-eQTL were significantly co-localizing (H4>0.8). 
GO enrichment analysis found that trans-eGenes are enriched for transcription 
factors, but clearly not all trans-eGenes encode transcription factors. 
5.3.2 Conditional analysis based on GEMMA controls the false positive rate 
Figure 5.1 Manhattan plot of trans-eQTL for DNTTIP2 on Chromosome 1. 
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Most of the samples in the FHS are genetically related with other samples, so to 
control for the relatedness and the potential population structure, I applied GEMMA’s 
mixed linear model. GEMMA is a widely used method in mixed linear modelling. 
Compared with other MLM-based methods, GEMMA is an efficient exact method, 
estimating variance components for each variant resulting in a better control for false 
positive and also a large statistical power. 
To evaluate the control of the false positive rate, I randomly chose 20 genes, and 
conducted eQTL detection with genome-wide variants. Analysis of genomic inflation 
factors for the 20 chosen genes shows that all these genes have a lambda around 1 (Table 
5.1), indicating good control of the false positive rate. Figure 5.1 and Figure 5.2 show the 
Manhattan plot for one trans-eQTL signal, and corresponding Q-Q plot, for quality 
evaluation of a randomly chosen gene, DNTTIP2.  Despite the excess of small P-values 
greater than NLP4 at target trans-eQTL, there is no genome-wide inflation. 
Figure 5.2   QQ-plot for the DNTTIP2 gene. 
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Table 5.1 Genomic inflation factor for 20 random genes in FHS. 
Gene Heritability Lambda 
DNTTIP2 0.032 1.001 
HELLS 0.322 0.947 
PTPN11 0.049 1.001 
PARP4 0.205 0.970 
ZFYVE26 0.057 0.994 
LPCAT2 0.213 0.997 
SNX20 0.062 1.009 
VPS4A 1E-05 0.996 
PNMT 0.007 0.997 
OR7G2 1E-05 0.968 
CBLN4 1E-05 0.993 
DHX35 0.079 0.988 
CELSR1 0.036 1.000 
LAMP3 0.055 1.007 
NSUN3 0.420 1.000 
CASP3 0.180 0.990 
THAP6 0.034 1.003 
POM121L12 1E-05 0.967 
CDKL5 0.105 0.997 
TAF7L 0.023 1.005 
 
5.3.3 Effective sample size estimation. 
As the effective sample size was not dramatically different from the actual sample 
size (mean 𝑁𝑁eff over all 20 genes was 4,837; median 𝑁𝑁eff=4,865 as compared to actual 𝑁𝑁 = 
5,075; Table 5.2), relatedness is not likely to influence the results of integrated meta-
analysis considerably, so I opted to use the actual sample size as a weight in the meta-
analysis. 
Table 5.2 Effective sample size of random 20 genes in FHS. 
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Gene N1eff N2eff 
DNTTIP2 4907 4976 
HELLS 4383 4829 
PTPN11 4850 4970 
PARP4 4506 4445 
ZFYVE26 4835 5033 
LPCAT2 4500 4600 
SNX20 4828 5024 
VPS4A 5026 4900 
PNMT 4999 4977 
OR7G2 5026 4984 
CBLN4 5031 4971 
DHX35 4769 5073 
CELSR1 4901 4744 
LAMP3 4837 4810 
NSUN3 4336 4519 
CASP3 4559 4648 
THAP6 4900 4813 
POM121L12 5027 4828 
CDKL5 4702 4593 
TAF7L 4938 5005 
 
5.3.4 Comparison with trans-eQTL estimates in the eQTLgen Consortium 
With the strategy developed to detect trans-eQTL in structured populations, I 
conducted trans-eQTL in the FHS data set. I applied the criteria that any variant was 
determined to be significant, if there is no absolute Z-score from permutations larger that 
in real data, which was demonstrated to be enough to have a FDR control below 0.05 
(Westra et al., 2013). After eQTL detection, I compared my results with other data in the 
eQTLgen Consortium. 
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Before the detection of trans-eQTL, I first conducted cis-eQTL detection, and a 
total of 7,274 associations were found to be significant. Cross-validation with other 
platform data indicated a platform-bias. For FHS cis-eQTL, the best concordance was 
found in NTR-NESDA, which is also an Affymetrix platform: among the explored 6,388 
(87.8%) FHS associations, 50.1% replicated in NTR-NESDA, and 97.2% of the shared 
signals had same direction of effect (Figure 5.3).  By contrast, in an Illumina data set, 4,510 
(62.0%) of the FHS associations could be tested, and 74.6% of the tested associations were 
replicated with only 89.7% showing consistent direction of effect (Figure 5.4). Similarly, 
replication in an RNA-seq dataset was also less than for the same platform. These results 
serve as a further reminder for researchers to be aware of platform-specific biases in eQTL 
analysis. 
 
Figure 5.3 Cis-eQTL comparison between FHS and Affymetrix data set. 
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 By contrast, trans-eQT results are free of plat-form bias, and shown high replicate 
rate. In summary, I detected a total of 4,422 significant associations in FHS dataset. To 
validate the accuracy of my trans-eQTL detection, I performed comparisons with trans-
eQTL results based on other data set in eQTLgen Consortium (Figures 5.5, 5.6). Cross-
comparison demonstrates that trans-eQTL results in FHS have similar concordance levels. 
 
Figure 5.4 Cis-eQTL comparison between FHS and Illumina (left) and RNA-seq 
(right) data sets. 
 
Figure 5.5 Trans-eQTL comparison between FHS and Affymetrix data set. 
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Comparing with meta-analysis results of 1,7000 individuals on the Illumina 
platform, I contrasted 3,977 (89.9%) associations, and 60.5% of the tested associations 
from FHS replicated, with 98.1% of these showing the same direction of effect size. 
Similarly, I measured the replication rate in RNA-seq trans-eQTL results, and all of the 
significant trans-eQTL in FHS could be tested, of which 65.9% replicated, 98.8% showing 
the same direction (Figure 5.6). I thus did not detect a higher concordance with NTR-
NESDA based on Affymetrix U291 array, since even though (because of the smaller 
sample size (2,767)), only a third could be evaluated, 99.5% had the same direction of 
effect (Figure 5.5). 
5.4 Conclusion 
In this chapter, I mainly described the trans-eQTL method in a structured 
population. In trans-eQTL detection, the major hindering factor is that millions of variants 
are tested, so multiple test correction reduces statistical power. To overcome the limitation 
and improve the statistical power to find trans-eQTL signals, I applied a mixed linear model 
Figure 5.6 Trans-eQTL comparison between FHS and two Illumina (left) and 
RNA-seq (right) data sets 
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method, also utilizing a well-designed permutation method. My association strategy has 
good control of the false positive rate, and the detected signals have good consistency with 
results based other datasets. Unexpectedly, the comparisons of detected eQTL signals in 
different platforms revealed that the detection of cis-eQTL is more vulnerable to platform 
bias than trans-eQTL. This phenomenon may result from the fact that the design strategy 
difference: in Illumina platform, the expression abundance is measured by the 
hybridization signals of 50 bp probes, while in Affymetrix, expression is measured by a set 
of probes targeting most of the exon region, and in RNA-seq, the expression was measured 
by the mapped sequenced reads.  
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CHAPTER 6  
CONCLUSION AND DISCUSSION 
In this dissertation, I have mainly focused on solving two problems in current 
human genetics: 1. Whether or not the expression of genes tends to be regulated by multiple 
eQTL; 2. Why GWAS hits are not more commonly found to co-localize with eQTL. My 
conclusion is that there are two reasons for the low co-localization level, one is the limited 
statistical power, and the other is regulation by multiple-causal variants.  
To address these two problems, I collected two datasets with large sample sizes to 
improve the statistical power to detect true, biological eQTL signals, and also developed a 
statistical method to perform multiple eQTL detection with control for relatedness and 
population structure. In Chapter 2, to demonstrate the idea of constraints brought by 
multiple eQTL regulation in current QTL analysis, I performed massive simulations based 
on real data to demonstrate that currently used methods have low power to detect co-
localization signals in the presence of multiple eQTL regulation. In Chapter 3, I described 
a method named PolyQTL, which I developed to solve the potential problem of relatedness 
and population structure, which may be common when combining samples from diverse 
populations. In Chapter 4, I applied my method to real data, explored the eQTL signals 
overlapping between three expression platforms, and also used it to evaluate GWAS-eQTL 
co-localization.  I used it to find causal genes and causal variants thought to function as 
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eQTL which affect human complex traits or diseases. In Chapter 5, I described my work 
as a member of the eQTLgen Consortium. 
Power is defined as the likelihood that a study will detect an effect when there is an 







dx, in which, α is the significance 
level, λ is the non-centrality parameter, calculated as beta/(sqrt(variance)/n) with beta the 
allelic effect size, n is the sample size, and the variance is the phenotype variance. From 
this formula, for a given significance level, we can see that the larger the value of λ, the 
larger power we have.  In order to attain a large λ, we require either large beta, small 
variance or large sample size n. Because of the limited availability of samples in current 
eQTL applications (most published studies contain less than 1000 samples), low power 
hampers the possibility to detect subtle effect eQTL. In addition, the phenomenon of 
winner’s curse further complicates the situation, since non-causal variants with an 
overestimated effect size are often chosen.  Although in this study, my colleagues and I 
collected an unusually large set of samples to detect cis-eQTL, only half of the genes were 
found to be regulated by eQTL, and the replication rate is still low for secondary cis-eQTL. 
It is thus necessary to continue to gather more samples. Currently, the sample size used in 
my studies is too small to consistently support detection of significant secondary signals in 
human cis-eQTL studies. Vosa et al (in preparation) show by meta-analysis that with more 
than 30,000 samples, we can detect cis-eQTL for almost all explored genes in human blood, 
demonstrating the prevalence of genetic regulation of gene expression. If I could extend 
the analysis to a larger cohort, I would have more power to detect the secondary signals, 
and reveal their role in traits and disease.  
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When gene expression is regulated by multiple eQTL, estimation of the effect sizes 
of explored variants will be influenced by the combination of multiple causal variants, 
depending on the LD structure at the locus. My results do reveal that gene expression in 
human blood tissue are largely regulated by multiple eQTL, and that cis-eQTL are to some 
extent shared when measurement of transcript abundance is performed on different 
expression platforms. Co-localization based on multiple-eQTL does find that for as many 
as 15% of genes, it is secondary cis-eQTL, instead of primary signals, that co-localize with 
GWAS hits.  These secondary signals may be the ones that function as expression 
regulatory factors to affect human complex traits and diseases, raising the question of why 
the primary signals are not GWAS hits.  
This result is puzzling, and leads me to consider potential biological mechanisms. 
There are two main possibilities. One is that if there are two causal variants that affect 
phenotypic traits through expression, due to low power in GWAS detection, the variant 
with the smaller effect size may finally be chosen and reported, while in eQTL detection, 
both of the two causal variants are found with conditional statistical analysis. The second 
possibility is that only certain specific cell types are associated with phenotypic traits or 
diseases, and the secondary cis-eQTL only functions in these cell types.  Since I have 
measured gene expression abundance in whole blood consisting of a mixture of over a 
dozen common cell types, the influence of secondary eQTL causal variant is diluted. 
Although some studies based on cell type specific expression have revealed that only a 
limited proportion of GWAS hits co-localize with cell eQTL signals, I anticipate that if I 
could collect more cell-specific samples (for example by single cell RNA-seq of peripheral 
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blood), and perform cell-specific eQTL, I could resolve more co-localized eQTL-GWAS 
variants. 
  In my studies, biological annotation information has not been used. Apart from the 
statistical association signals between genotype and phenotype, it is also possible to obtain 
information from biological and functional genomic contexts. For example, as shown in 
my eQTL-GWAS co-localization analysis, transcription factors are enriched to affect 
phenotype through gene expression. By integrating these kinds of biological information 
into the statistical model, I should be able to further enhance the power to find causal 
variants and genes. Some developed methods (Yang et al., 2017) implicitly make the 
assumption that variants associated with one trait, should also affect other traits.  For 
instance, COLOC chooses the default prior that a variant affects either expression or 
phenotype to be 10-4, while the prior that the variant affects both traits is 10-5, which 
indicates an enrichment of 1000 fold (10-5/(10-4*10-4)). Although this kind of assumption 
is now still controversial, some studies reveal that integrating biological annotation into 
the model may increases power (Yang et al., 2017). Results from the ENCODE and 
ROADMAP Consortia (2015) have provided a rich atlas of functional information, so 
extension of my PolyQTL method to jointly integrate functional and association data 
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